
Timothy M Pawlik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4707419/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Surgeon Strategies to Patient-Centered Decision-making in Cancer Care: Validation and Applications of a Conceptual Model. Journal of Cancer Education, 2022, 37, 1719-1726.	1.3	1
2	Rural hospitals are not associated with worse postoperative outcomes for colon cancer surgery. Journal of Rural Health, 2022, 38, 650-659.	2.9	10
3	The impact of social vulnerability subthemes on postoperative outcomes differs by racial/ethnic minority status. American Journal of Surgery, 2022, 223, 353-359.	1.8	9
4	A contemporary reassessment of the US surgical workforce through 2050 predicts continued shortages and increased productivity demands. American Journal of Surgery, 2022, 223, 28-35.	1.8	38
5	The Influence of Patient and Provider Religious and Spiritual Beliefs on Treatment Decision Making in the Cancer Care Context. Medical Decision Making, 2022, 42, 125-134.	2.4	5
6	Timing and Severity of Postoperative Complications and Associated 30-Day Mortality Following Hepatic Resection: a National Surgical Quality Improvement Project Study. Journal of Gastrointestinal Surgery, 2022, 26, 314-322.	1.7	2
7	Assessment of Textbook Outcome After Surgery for Stage I/II Non-small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 1351-1359.	0.6	10
8	Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 315-324.	1.5	16
9	Social vulnerability and fragmentation of postoperative surgical care among patients undergoing hepatopancreatic surgery. Surgery, 2022, 171, 1043-1050.	1.9	8
10	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 1220-1229.	1.5	8
11	Trends in Textbook Outcomes over Time: Are Optimal Outcomes Following Complex Gastrointestinal Surgery for Cancer Increasing?. Journal of Gastrointestinal Surgery, 2022, 26, 50-59.	1.7	18
12	Does the Volume-Outcome Association in Pancreas Cancer Surgery Justify Regionalization of Care? A Review of Current Controversies. Annals of Surgical Oncology, 2022, 29, 1257-1268.	1.5	18
13	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2022, 275, e773-e780.	4.2	13
14	Is Hospital Occupancy Rate Associated With Postoperative Outcomes Among Patients Undergoing Hepatopancreatic Surgery?. Annals of Surgery, 2022, 276, 153-158.	4.2	8
15	SRY is a Key Mediator of Sexual Dimorphism in Hepatic Ischemia/Reperfusion Injury. Annals of Surgery, 2022, 276, 345-356.	4.2	8
16	Imaging of Colorectal Liver Metastasis. Journal of Gastrointestinal Surgery, 2022, 26, 245-257.	1.7	10
17	Implications of intensive care unit admissions among medicare beneficiaries following resection of pancreatic cancer. Journal of Surgical Oncology, 2022, 125, 405-413.	1.7	3
18	Surgical management of intrahepatic cholangiocarcinoma. Expert Review of Anticancer Therapy, 2022, 22, 27-38.	2.4	16

#	Article	IF	CITATIONS
19	Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice. Journal of Gastrointestinal Surgery, 2022, 26, 1021-1029.	1.7	8
20	Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matching analysis. European Journal of Surgical Oncology, 2022, 48, 1078-1086.	1.0	1
21	Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. Frontiers in Oncology, 2022, 12, 832405.	2.8	7
22	Fragmentation of practice: The adverse effect of surgeons moving around. Surgery, 2022, 172, 480-485.	1.9	3
23	Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young <i>versus</i> the elderly: multicentre propensity score-matching study. BJS Open, 2022, 6, .	1.7	4
24	Mexico: the Inaugural International Chapter of the Society for Surgery of the Alimentary Tract. Journal of Gastrointestinal Surgery, 2022, 26, 519-522.	1.7	0
25	A Scoping Review of the Classification, Diagnosis, and Management of Hepatic Adenomas. Journal of Gastrointestinal Surgery, 2022, 26, 965-978.	1.7	8
26	Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Surgery, 2022, 171, 1464-1470.	1.9	15
27	Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: Ileocecectomy Versus Right Hemicolectomy. Journal of Gastrointestinal Surgery, 2022, 26, 1266-1274.	1.7	4
28	Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. British Journal of Surgery, 2022, 109, 610-616.	0.3	13
29	Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Annals of Surgical Oncology, 2022, 29, 4291-4303.	1.5	23
30	Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, 29, 4326-4334.	1.5	7
31	ASO Visual Abstract: Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Annals of Surgical Oncology, 2022, , 1.	1.5	0
32	The 2020 Pandemics: Lessons Learned in Academic Surgery and Beyond. Journal of Surgical Research, 2022, 276, A1-A6.	1.6	1
33	Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. Practical Radiation Oncology, 2022, 12, 511-523.	2.1	5
34	Real-time mortality risk calculator following pancreatoduodenectomy: quantifying the impact of perioperative events. Hpb, 2022, , .	0.3	0
35	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. Journal of Surgical Oncology, 2022, 125, 621-630.	1.7	9
36	Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opinion on Pharmacotherapy, 2022, 23, 473-481.	1.8	1

#	Article	IF	CITATIONS
37	ASO Visual Abstract: Association of Preoperative Body Mass Index with Surgical Textbook Outcomes following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Study of 1206 Patients. Annals of Surgical Oncology, 2022, , 1.	1.5	0
38	Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 5177-5185.	1.5	4
39	Association of Preoperative Body Mass Index with Surgical Textbook Outcomes Following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Study of 1206 Patients. Annals of Surgical Oncology, 2022, 29, 4278-4286.	1.5	14
40	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 2018.	3.7	15
41	Development and validation of risk stratification tool for prediction of increased dependence using preoperative frailty after hepatopancreatic surgery. Surgery, 2022, , .	1.9	0
42	The Impact of Tumor Burden on Survival Differs by Morphological Subtype Among Patients Diagnosed with Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2022, 26, 1764-1765.	1.7	2
43	Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: A multi-institutional analysis. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S302-S302.	0.1	3
44	Association of adjuvant radiotherapy with long-term overall and recurrence-free survival following hepatectomy for hepatocellular carcinoma: A multicenter propensity-matched study. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S311-S311.	0.1	1
45	Risk factors and long-term prognosis of BCLC stage 0/A hepatocellular carcinoma for beyond milan recurrence after hepatectomy: A multicenter observational study. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S310-S310.	0.1	0
46	Association of preoperative body mass index with surgical textbook outcomes following hepatectomy for hepatocellular carcinoma: A multicenter study of 1,206 patients. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S202-S202.	0.1	0
47	Long-term oncologic prognosis after hepatectomy for hepatocellular carcinoma: Differences between the young (â‰\$5 years old) and the elderly (≥ 70 years old). Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S305-S305.	0.1	0
48	Liver resection for a solitary huge hepatocellular carcinoma (≥ 10 cm): A large-scale multicenter observational study. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S37-S37.	0.1	0
49	Comment on: "Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancerâ€: Annals of Surgical Oncology, 2022, , 1.	1.5	0
50	Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 2208.	3.7	10
51	Using Artificial Intelligence to Find the Optimal Margin Width in Hepatectomy for Colorectal Cancer Liver Metastases. JAMA Surgery, 2022, 157, e221819.	4.3	16
52	Using Machine Learning to Preoperatively Stratify Prognosis among Patients with Gallbladder Cancer: A Multi-Institutional Analysis. Hpb, 2022, , .	0.3	1
53	A Comprehensive Review of Hepatic Hemangioma Management. Journal of Gastrointestinal Surgery, 2022, 26, 1998-2007.	1.7	13
54	Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2022, 29, 7605-7614.	1.5	7

#	Article	IF	CITATIONS
55	Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping. Cancers, 2022, 14, 3284.	3.7	11
56	A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101534.	1.5	19
57	Utilization of High-Volume Hospitals for High-Risk Cancer Surgery in California Following Medicaid Expansion. Journal of Gastrointestinal Surgery, 2021, 25, 1875-1884.	1.7	6
58	County-Level Variation in Utilization of Surgical Resection for Early-Stage Hepatopancreatic Cancer Among Medicare Beneficiaries in the USA. Journal of Gastrointestinal Surgery, 2021, 25, 1736-1744.	1.7	3
59	Mental illness is associated with increased risk of suicidal ideation among cancer surgical patients. American Journal of Surgery, 2021, 222, 126-132.	1.8	12
60	Refusal of Surgery Among Patients with Early-Stage Hepato-Pancreato-Biliary Cancers: Predictive Factors and Outcomes. Journal of Gastrointestinal Surgery, 2021, 25, 1573-1575.	1.7	2
61	Travel Patterns among Patients Undergoing Hepatic Resection in California: Does Driving Further for Care Improve Outcomes?. Journal of Gastrointestinal Surgery, 2021, 25, 1471-1478.	1.7	5
62	Preoperative Medical Referral Prior to Hepatopancreatic Surgery—Is It Worth it?. Journal of Gastrointestinal Surgery, 2021, 25, 954-961.	1.7	0
63	Variation in Drain Management Among Patients Undergoing Major Hepatectomy. Journal of Gastrointestinal Surgery, 2021, 25, 962-970.	1.7	3
64	Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 155-161.	1.7	23
65	Comparison of lymph node evaluation and yield among patients undergoing open and minimally invasive surgery for gallbladder adenocarcinoma. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 2223-2228.	2.4	11
66	A Wearable Augmented Reality Navigation System for Surgical Telementoring Based on Microsoft HoloLens. Annals of Biomedical Engineering, 2021, 49, 287-298.	2.5	36
67	Comparing Surgeon Approaches to Patient-Centered Cancer Care Using Vignette Methodology. Journal of Gastrointestinal Surgery, 2021, 25, 1307-1315.	1.7	1
68	Quality of Care Among Medicare Patients Undergoing Pancreatic Surgery: Safety Grade, Magnet Recognition, and Leapfrog Minimum Volume Standards—Which Quality Benchmark Matters?. Journal of Gastrointestinal Surgery, 2021, 25, 269-277.	1.7	19
69	Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 125-133.	1.7	38
70	ASO Author Reflections: How Does Social Vulnerability Impact Hospice Utilization Among Patients Undergoing Cancer Surgery?. Annals of Surgical Oncology, 2021, 28, 1927-1928.	1.5	0
71	Association of County-Level Social Vulnerability with Elective Versus Non-elective Colorectal Surgery. Journal of Gastrointestinal Surgery, 2021, 25, 786-794.	1.7	54
72	Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 1156-1163.	1.7	20

#	Article	IF	CITATIONS
73	Association of Neighborhood Characteristics with Utilization of High-Volume Hospitals Among Patients Undergoing High-Risk Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 617-631.	1.5	42
74	Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma. European Journal of Surgical Oncology, 2021, 47, 660-666.	1.0	20
75	Tumor Necrosis Impacts Prognosis of Patients Undergoing Curative-Intent Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 797-805.	1.5	28
76	Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?. Annals of Surgical Oncology, 2021, 28, 1970-1978.	1.5	30
77	Inter-surgeon variability is associated with likelihood to undergo minimally invasive hepatectomy and postoperative mortality. Hpb, 2021, 23, 840-846.	0.3	1
78	The association of Hospital Medicare beneficiary payer-mix, national quality rankings and outcomes following hepatopancreatic surgery. American Journal of Surgery, 2021, 221, 492-496.	1.8	2
79	Assessment of hospital quality and safety standards among Medicare beneficiaries undergoing surgery for cancer. Surgery, 2021, 169, 573-579.	1.9	4
80	Management of Metastatic Liver Tumors. Surgical Oncology Clinics of North America, 2021, 30, xiii-xiv.	1.5	0
81	Race/Ethnicity and County-Level Social Vulnerability Impact Hospice Utilization Among Patients Undergoing Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 1918-1926.	1.5	26
82	Sexâ€based differences in time to surgical care among pancreatic cancer patients: A national study of Medicare beneficiaries. Journal of Surgical Oncology, 2021, 123, 236-244.	1.7	11
83	The impact of individual surgeon on the likelihood of minimal invasive surgery among Medicare beneficiaries undergoing pancreatic resection. Surgery, 2021, 169, 550-556.	1.9	Ο
84	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surgical Oncology, 2021, 37, 101492.	1.6	15
85	Insurance status and highâ€volume surgical cancer: Access to highâ€quality cancer care. Cancer, 2021, 127, 507-509.	4.1	2
86	ASO Visual Abstract: Defining and Predicting Early Recurrence After Resection for Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 426-427.	1.5	0
87	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Hpb, 2021, 23, 25-36.	0.3	16
88	Assessment of Cancer Center Variation in Textbook Oncologic Outcomes Following Colectomy for Adenocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 775-785.	1.7	26
89	Trends in the Geospatial Distribution of Inpatient Adult Surgical Services across the United States. Annals of Surgery, 2021, 273, 121-127.	4.2	49
90	Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis. Surgery, 2021, 169, 911-920.	1.9	29

#	Article	IF	CITATIONS
91	ASO Author Reflections: Tumor Burden in Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 1979-1980.	1.5	0
92	Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. Journal of Surgical Oncology, 2021, 123, 978-985.	1.7	7
93	Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 2368-2376.	1.7	18
94	Machine learning predicts unpredicted deaths with high accuracy following hepatopancreatic surgery. Hepatobiliary Surgery and Nutrition, 2021, 10, 20-30.	1.5	15
95	End-of-Life Hospice Use and Medicare Expenditures AmongÂPatients Dying of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 5414-5422.	1.5	10
96	Impact of Metabolic Syndrome on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Hepatectomy. Journal of Gastrointestinal Surgery, 2021, 25, 2545-2552.	1.7	6
97	Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. Hepatology International, 2021, 15, 459-471.	4.2	1
98	Recurrence of Nonâ€functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burdenâ€Based Prediction Model. World Journal of Surgery, 2021, 45, 2134-2141.	1.6	2
99	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. Hpb, 2021, 23, 413-421.	0.3	18
100	Association of social vulnerability with the use of high-volume and Magnet recognition hospitals for hepatopancreatic cancer surgery. Surgery, 2021, 170, 571-578.	1.9	21
101	Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml). Journal of Hepatocellular Carcinoma, 2021, Volume 8, 103-118.	3.7	10
102	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 4205-4213.	1.5	19
103	Association of Depression with In-Patient and Post-Discharge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. Annals of Surgical Oncology, 2021, 28, 6525-6534.	1.5	10
104	Complications After Complex Gastrointestinal Cancer Surgery: Benefits and Costs Associated with Inter-hospital Transfer Among Medicare Beneficiaries. Journal of Gastrointestinal Surgery, 2021, 25, 1370-1379.	1.7	3
105	High Social Vulnerability and "Textbook Outcomes―after Cancer Operation. Journal of the American College of Surgeons, 2021, 232, 351-359.	O.5	95
106	Trends in Discharge Disposition Following Hepatectomy for Hepatocellular Carcinoma Among Medicare Beneficiaries. Journal of Gastrointestinal Surgery, 2021, 25, 2842-2850.	1.7	2
107	Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World Journal of Gastrointestinal Oncology, 2021, 13, 197-215.	2.0	13
108	Impact of Race/Ethnicity and County-Level Vulnerability on Receipt of Surgery Among Older Medicare Beneficiaries With the Diagnosis of Early Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 6309-6316.	1.5	30

#	Article	IF	CITATIONS
109	Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status. Journal of the American College of Surgeons, 2021, 232, 590-598.	0.5	14
110	MOOSE Reporting Guidelines for Meta-analyses of Observational Studies. JAMA Surgery, 2021, 156, 787-788.	4.3	199
111	Liver metastases. Nature Reviews Disease Primers, 2021, 7, 27.	30.5	190
112	ASO Visual Abstract: Impact ofÂResidentialÂRacialÂIntegration onÂPostoperativeÂOutcomesÂAmongÂMedicareÂBeneficiariesÂUndergoingÂResection forÂCancer. Annals of Surgical Oncology, 2021, 28, 416.	1.5	0
113	Training Paradigms in Hepato-Pancreatico-Biliary Surgery: an Overview of the Different Fellowship Pathways. Journal of Gastrointestinal Surgery, 2021, 25, 2119-2128.	1.7	11
114	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers, 2021, 13, 2242.	3.7	6
115	Hepatopancreatic Surgery in the Rural United States: Variation in Outcomes at Critical Access Hospitals. Journal of Surgical Research, 2021, 261, 123-129.	1.6	4
116	Disparities in NCCNÂGuidelineÂCompliant Care for Resectable Cholangiocarcinoma at Minority-Serving Versus Non-Minority-Serving Hospitals. Annals of Surgical Oncology, 2021, 28, 8162-8171.	1.5	16
117	ASO Visual Abstract: Association of Depression with In-Patient and Postdischarge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. Annals of Surgical Oncology, 2021, 28, 429-429.	1.5	2
118	Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 7624-7633.	1.5	4
119	Assessment of Magnet status and Textbook Outcomes among medicare beneficiaries undergoing hepatoâ€pancreatic surgery for cancer. Journal of Surgical Oncology, 2021, 124, 334-342.	1.7	7
120	Impact of Psychiatric Illness on Survival among Patients with Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 3242-3243.	1.7	5
121	A higher hospital case mix index increases the odds of achieving a textbook outcome after hepatopancreatic surgery in the Medicare population. Surgery, 2021, 170, 1525-1531.	1.9	7
122	Profiles in social vulnerability: The association of social determinants of health with postoperative surgical outcomes. Surgery, 2021, 170, 1777-1784.	1.9	59
123	Association of County-Level Racial Diversity and Likelihood of a Textbook Outcome Following Pancreas Surgery. Annals of Surgical Oncology, 2021, 28, 8076-8084.	1.5	14
124	Age-Based Left-Digit Bias in the Management of Acute Cholecystitis. Journal of Gastrointestinal Surgery, 2021, 25, 3239-3241.	1.7	6
125	Surgical Strategies for Bismuth Type I and II Hilar Cholangiocarcinoma: Impact on Long-Term Outcomes. Journal of Gastrointestinal Surgery, 2021, 25, 3084-3091.	1.7	5
126	ASO Author Reflections: County-Level Racial Diversity is Associated with Textbook Outcomes for Pancreatic Surgery. Annals of Surgical Oncology, 2021, 28, 8085-8086.	1.5	0

#	Article	IF	CITATIONS
127	Editorial: Enhanced Recovery after Surgery Pathways: Improving the Perioperative Experience and Outcomes of Cancer Surgery Patients. Annals of Surgical Oncology, 2021, 28, 6929-6931.	1.5	0
128	Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings. Surgical Oncology, 2021, 37, 101529.	1.6	8
129	Patient Social Vulnerability and Hospital Community Racial/Ethnic Integration: Do All Patients Undergoing Pancreatectomy Receive the Same Care Across Hospitals?. Annals of Surgery, 2021, 274, 508-515.	4.2	11
130	The value of lymphadenectomy in surgical resection of perihilar cholangiocarcinoma: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2021, 26, 1575-1586.	2.2	4
131	Emergency Department Utilization Following Hepatopancreatic Surgery Among Medicare Beneficiaries. Journal of Gastrointestinal Surgery, 2021, 25, 3099-3107.	1.7	0
132	Resection of intermediate stage hepatocellular carcinoma. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, S12-S12.	0.1	0
133	Optimal hepatic surgery: Are we making progress in North America?. Surgery, 2021, 170, 1741-1748.	1.9	8
134	Impact of Perioperative Thromboembolic Complications on Future Long-term Risk of Venous Thromboembolism among Medicare Beneficiaries Undergoing Complex Gastrointestinal Surgery. Journal of Gastrointestinal Surgery, 2021, 25, 3064-3073.	1.7	1
135	Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. Frontiers in Oncology, 2021, 11, 700228.	2.8	6
136	Geographic Disparities in Oncologic Treatment and Outcomes: The Urban–Rural Divide. Annals of Surgical Oncology, 2021, 28, 8011-8013.	1.5	4
137	The State of Immunotherapy in Hepatobiliary Cancers. Cells, 2021, 10, 2096.	4.1	18
138	State-of-the-art surgery for hepatocellular carcinoma. Langenbeck's Archives of Surgery, 2021, 406, 2151-2162.	1.9	12
139	Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 8174-8185.	1.5	14
140	Cancer Care in the Incarcerated Population. JAMA Surgery, 2021, 156, 964.	4.3	8
141	Survival Benefit of Primary Tumor Resection Among Elderly Patients with Pancreatic Neuroendocrine Tumors. World Journal of Surgery, 2021, 45, 3643-3651.	1.6	9
142	Is Textbook Oncologic Outcome a Valid Hospital-Quality Metric after High-Risk Surgical Oncology Procedures?. Annals of Surgical Oncology, 2021, 28, 8028-8045.	1.5	30
143	MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. Molecular Cancer, 2021, 20, 118.	19.2	24
144	Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. American Journal of Surgery, 2021, 222, 570-576.	1.8	0

#	Article	IF	CITATIONS
145	Does minimally invasive pancreaticoduodenectomy increase the chance of a textbook oncologic outcome?. Surgery, 2021, 170, 880-888.	1.9	11
146	ASO Visual Abstract: Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 734-735.	1.5	5
147	Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature. World Journal of Gastrointestinal Oncology, 2021, 13, 1043-1061.	2.0	21
148	Inspirational Women in Surgery: Olga Jonasson, the Legacy of the First Female Chair of an Academic Department of Surgery. World Journal of Surgery, 2021, , 1.	1.6	0
149	MG53 suppresses NF- $\hat{I}^{e}B$ activation to mitigate age-related heart failure. JCI Insight, 2021, 6, .	5.0	17
150	Healthcare provider self-reported observations and behaviors regarding their role in the spiritual care of cancer patients. Supportive Care in Cancer, 2021, 29, 4405-4412.	2.2	5
151	Dream big, think little: the impact of the AHPBA. Hpb, 2021, 23, S443-S447.	0.3	1
152	Evaluation of Red Blood Cell Transfusion Practice and Knowledge Among Cancer Surgeons. Journal of Gastrointestinal Surgery, 2021, 25, 2928-2938.	1.7	4
153	Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer, 2021, 10, 137-150.	7.7	21
154	A narrative review: has regionalization truly achieved its intended goal in the surgical management of pancreatic cancer?. Chinese Clinical Oncology, 2021, 10, 46-46.	1.2	2
155	Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Annals of Surgery, 2021, 274, e1187-e1195.	4.2	105
156	Response to the Comment on "Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis― Annals of Surgery, 2021, 274, e743.	4.2	18
157	County-level Social Vulnerability is Associated With Worse Surgical Outcomes Especially Among Minority Patients. Annals of Surgery, 2021, 274, 881-891.	4.2	103
158	Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. Journal of Clinical Medicine, 2021, 10, 104.	2.4	24
159	The Immunology of Hepatocellular Carcinoma. Vaccines, 2021, 9, 1184.	4.4	41
160	ASO Visual Abstract: Does the Volume-Outcome Association in Pancreas Cancer Justify Regionalization of Care? A Review of Current Controversies. Annals of Surgical Oncology, 2021, 28, 748.	1.5	2
161	Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies. Cancers, 2021, 13, 5169.	3.7	18
162	Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma. Journal of Hematology and Oncology, 2021, 14, 165.	17.0	15

#	Article	IF	CITATIONS
163	Spiritual Motivations to Practice Medicine: A Survey of Cancer Care Providers. American Journal of Hospice and Palliative Medicine, 2021, , 104990912110498.	1.4	Ο
164	Patterns of health care utilization among Medicare beneficiaries diagnosed with pancreatic adenocarcinoma. American Journal of Surgery, 2021, , .	1.8	0
165	Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma. Hepatic Medicine: Evidence and Research, 2021, Volume 13, 93-104.	2.5	2
166	A mixedâ€methods approach to comparing perceptions of cancer patients' and cancer care providers' religious and spiritual beliefs, behaviours, and attitudes. European Journal of Cancer Care, 2021, 30, e13390.	1.5	1
167	Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure. Frontiers in Oncology, 2021, 11, 639235.	2.8	Ο
168	Response to the Comment on "Cancer Surgery During COVID-19: How We Move Forward― Annals of Surgery, 2021, 274, e828-e829.	4.2	0
169	Abstract 11086: MG53 Suppresses Nfl̂ºB Activation to Mitigate Age-Related Heart Failure. Circulation, 2021, 144, .	1.6	Ο
170	Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC. Journal of Gastrointestinal Surgery, 2020, 24, 320-329.	1.7	34
171	Outcomes of Patients with Scirrhous Hepatocellular Carcinoma: Insights from the National Cancer Database. Journal of Gastrointestinal Surgery, 2020, 24, 1049-1060.	1.7	5
172	Insurance Coverage Type Impacts Hospitalization Patterns Among Patients with Hepatopancreatic Malignancies. Journal of Gastrointestinal Surgery, 2020, 24, 1320-1329.	1.7	10
173	Evaluation of the ACS NSQIP Surgical Risk Calculator in Elderly Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 551-559.	1.7	24
174	Minimally Invasive Liver Resection for Early-Stage Hepatocellular Carcinoma: Inconsistent Outcomes from Matched or Weighted Cohorts. Journal of Gastrointestinal Surgery, 2020, 24, 560-568.	1.7	5
175	Textbook Outcomes Among Medicare Patients Undergoing Hepatopancreatic Surgery. Annals of Surgery, 2020, 271, 1116-1123.	4.2	158
176	Is Annual Preoperative Utilization an Indicator of Postoperative Surgical Outcomes? A Study in Medicare Expenditure. World Journal of Surgery, 2020, 44, 108-114.	1.6	5
177	Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. Hpb, 2020, 22, 383-390.	0.3	17
178	Endoscopic Ultrasound-Guided Confocal Laser Endomicroscopy Increases Accuracy of Differentiation of Pancreatic Cystic Lesions. Clinical Gastroenterology and Hepatology, 2020, 18, 432-440.e6.	4.4	71
179	Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 552-560.	1.5	25
180	Hepatopancreatobiliary Surgery: the Role of Clinical Resources and Variation in Performance of Hospitals Located in "Distressed―Communities. Journal of Gastrointestinal Surgery, 2020, 24, 2277-2285.	1.7	3

#	Article	IF	CITATIONS
181	Use of Machine Learning for Prediction of Patient Risk of Postoperative Complications After Liver, Pancreatic, and Colorectal Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 1843-1851.	1.7	62
182	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. Hpb, 2020, 22, 215-223.	0.3	20
183	Impact of Surgeon Volume on Outcomes and Expenditure Among Medicare Beneficiaries Undergoing Liver Resection: the Effect of Minimally Invasive Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 1520-1529.	1.7	9
184	In-hospital Mortality Following Pancreatoduodenectomy: a Comprehensive Analysis. Journal of Gastrointestinal Surgery, 2020, 24, 1119-1126.	1.7	19
185	Effect of Surgical Margin Width on Patterns of Recurrence among Patients Undergoing RO Hepatectomy for T1 Hepatocellular Carcinoma: An International Multi-Institutional Analysis. Journal of Gastrointestinal Surgery, 2020, 24, 1552-1560.	1.7	37
186	Short-Term Outcomes of Patients Undergoing Portal Vein Embolization: an ACS-NSQIP Procedure-Targeted Hepatectomy Analysis. Journal of Gastrointestinal Surgery, 2020, 24, 1571-1580.	1.7	2
187	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. Surgery, 2020, 167, 352-357.	1.9	11
188	Factors associated with switching between low and super utilization in the surgical population: A study in medicare expenditure. American Journal of Surgery, 2020, 219, 1-7.	1.8	1
189	Trends in the Geospatial Distribution of Adult Inpatient Surgical Cancer Care Across the United States. Journal of Gastrointestinal Surgery, 2020, 24, 2127-2134.	1.7	14
190	Clinical Utility of Autologous Salvaged Blood: a Review. Journal of Gastrointestinal Surgery, 2020, 24, 464-472.	1.7	35
191	Patient Perceptions About the Role of Religion and Spirituality During Cancer Care. Journal of Religion and Health, 2020, 59, 1933-1945.	1.7	20
192	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Annals of Surgical Oncology, 2020, 27, 783-792.	1.5	20
193	ASO Author Reflections: Use of Machine Learning to Identify Patients with Intrahepatic Cholangiocarcinoma Who Could Benefit More from Neoadjuvant Therapies. Annals of Surgical Oncology, 2020, 27, 1120-1121.	1.5	2
194	A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated withÂResection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. Annals of Surgical Oncology, 2020, 27, 1110-1119.	1.5	41
195	Routine Intensive Care Unit Admission Following Liver Resection: What Is the Value Proposition?. Journal of Gastrointestinal Surgery, 2020, 24, 2491-2499.	1.7	8
196	Association between body mass index and postoperative morbidity after liver resection of hepatocellular carcinoma. Hpb, 2020, 22, 289-297.	0.3	13
197	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. Hpb, 2020, 22, 1149-1157.	0.3	13
198	Precision Medicine in Surgical Oncology. Surgical Oncology Clinics of North America, 2020, 29, xiii-xiv.	1.5	0

#	Article	IF	CITATIONS
199	Optimal Location for Centralization of Hospitals Performing Pancreas Resection in California. JAMA Surgery, 2020, 155, 261.	4.3	22
200	Hospital variation in Textbook Outcomes following curative-intent resection of hepatocellular carcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1305-1313.	0.3	45
201	Complex hepato-pancreato-biliary caseload during general surgery residency training: are we adequately training the next generation?. Hpb, 2020, 22, 603-610.	0.3	8
202	Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome. Hpb, 2020, 22, 622-629.	0.3	19
203	Impact of Preoperative Cholangitis on Short-term Outcomes Among Patients Undergoing Liver Resection. Journal of Gastrointestinal Surgery, 2020, 24, 2508-2516.	1.7	4
204	Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. Hpb, 2020, 22, 677-689.	0.3	35
205	Travel to a high volume hospital to undergo resection of gallbladder cancer: does it impact quality of care and long-term outcomes?. Hpb, 2020, 22, 41-49.	0.3	14
206	How Safe Are Safety-Net Hospitals? Opportunities to Improve Outcomes for Vulnerable Patients Undergoing Hepatopancreaticobiliary Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 2570-2578.	1.7	8
207	Interaction of Surgeon Volume and Nurse-to-Patient Ratio on Post-operative Outcomes of Medicare Beneficiaries Following Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2020, 24, 2551-2559.	1.7	13
208	Skilled nursing facility (SNF) utilization and impact of SNF star-quality ratings on outcomes following hepatectomy among Medicare beneficiaries. Hpb, 2020, 22, 109-115.	0.3	7
209	New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy, 2020, 21, 183-191.	1.8	9
210	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. Annals of Surgical Oncology, 2020, 27, 1203-1212.	1.5	21
211	Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients. Journal of Gastrointestinal Surgery, 2020, 24, 2756-2765.	1.7	5
212	Development and validation of a real-time mortality risk calculator before, during and after hepatectomy: an analysis of the ACS NSQIP database. Hpb, 2020, 22, 1158-1167.	0.3	2
213	The impact of liver resection on survival for locally advanced intrahepatic cholangiocarcinoma tumors: A propensity score analysis. European Journal of Surgical Oncology, 2020, 46, 632-637.	1.0	6
214	Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma. JAMA Oncology, 2020, 6, 255.	7.1	120
215	Preoperative continuity of care and its relationship with cost of hepatopancreatic surgery. Surgery, 2020, 168, 809-815.	1.9	4
216	Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons. Annals of Surgery, 2020, 272, 715-722.	4.2	53

#	Article	IF	CITATIONS
217	Emerging pathways for precision medicine in management of cholangiocarcinoma. Surgical Oncology, 2020, 35, 47-55.	1.6	5
218	Journal of Gastrointestinal Surgery: Commitment to Diversity and Inclusion in the Editorial Process. Journal of Gastrointestinal Surgery, 2020, 24, 2439-2440.	1.7	4
219	Cancer Surgery During COVID-19. Annals of Surgery, 2020, 272, e94-e95.	4.2	7
220	Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis. Surgery, 2020, 168, 497-503.	1.9	13
221	Is Patient Satisfaction Dictated by Quality of Care Among Patients Undergoing Complex Surgical Procedures for a Malignant Indication?. Annals of Surgical Oncology, 2020, 27, 3126-3135.	1.5	8
222	Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Review of Anticancer Therapy, 2020, 20, 765-773.	2.4	13
223	Apples to Oranges. Annals of Surgery, 2020, 272, e52.	4.2	5
224	Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surgery and Nutrition, 2020, 9, 440-451.	1.5	37
225	Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2020, 155, 823.	4.3	116
226	Quality Versus Costs Related to Gastrointestinal Surgery: Disentangling the Value Proposition. Journal of Gastrointestinal Surgery, 2020, 24, 2874-2883.	1.7	14
227	Clinical relevance of performing endoscopic ultrasoundâ€guided fineâ€needle biopsy for pancreatic neuroendocrine tumors less than 2 cm. Journal of Surgical Oncology, 2020, 122, 1393-1400.	1.7	15
228	A Cross-Sectional Evaluation of Quality of Life Among Patients with Hepatic Adenomas. Journal of Gastrointestinal Surgery, 2020, 24, 2862-2864.	1.7	1
229	Emerging Therapies in Thoracic Malignancies. Surgical Oncology Clinics of North America, 2020, 29, xiii-xiv.	1.5	Ο
230	Assessing prognosis in cholangiocarcinoma: a review of promising genetic markers and imaging approaches. Expert Opinion on Orphan Drugs, 2020, 8, 357-365.	0.8	1
231	Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. Annals of Surgery, 2020, 272, 574-581.	4.2	52
232	The Impact of Mental Illness on Postoperative Outcomes Among Medicare Beneficiaries. Annals of Surgery, 2020, 272, 419-425.	4.2	37
233	Relevance of Lymph Node Yield Following Neoadjuvant Therapy: Still a Valid Surgical Quality Metric?. Annals of Surgery, 2020, 272, 447-448.	4.2	1
234	Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097769.	3.2	25

#	Article	IF	CITATIONS
235	The association of neighborhood social vulnerability with surgical textbook outcomes among patients undergoing hepatopancreatic surgery. Surgery, 2020, 168, 868-875.	1.9	76
236	Multicenter analysis of long-term oncologic outcomes of hepatectomy for elderly patients with hepatocellular carcinoma. Hpb, 2020, 22, 1314-1323.	0.3	8
237	Assessing a Surgeon's Competency for High-Risk Procedures. JAMA Network Open, 2020, 3, e203888.	5.9	4
238	The Landmark Series: Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2859-2865.	1.5	16
239	Telemedicine: Patient-Provider Clinical Engagement During the COVID-19 Pandemic and Beyond. Journal of Gastrointestinal Surgery, 2020, 24, 1692-1697.	1.7	273
240	Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. Annals of Surgical Oncology, 2020, 27, 3318-3327.	1.5	59
241	Current Advances in Minimally Invasive Surgical Management of Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 2143-2149.	1.7	6
242	COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission. Annals of Surgical Oncology, 2020, 27, 2591-2599.	1.5	12
243	Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Oncologist, 2020, 25, e1541-e1551.	3.7	66
244	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. Journal of Surgical Oncology, 2020, 122, 442-449.	1.7	1
245	The management of surgical patients during the coronavirus disease 2019 (COVID-19) pandemic. Surgery, 2020, 168, 4-10.	1.9	23
246	Variation in value among hospitals performing complex cancer operations. Surgery, 2020, 168, 106-112.	1.9	9
247	Variations in Healthcare Expenditures Among Medicare Beneficiaries Undergoing Resection of Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 1863-1865.	1.7	Ο
248	A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. Annals of Surgical Oncology, 2020, 27, 5224-5232.	1.5	20
249	Health expenditures and financial burden among patients with major gastrointestinal cancers relative to other common cancers in the United States. Surgery, 2020, 167, 985-990.	1.9	7
250	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2020, 121, 1201-1208.	1.7	23
251	Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surgery and Nutrition, 2020, 9, 13-24.	1.5	11
252	The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2888-2901.	1.5	44

#	Article	IF	CITATIONS
253	Mentor of the Month Series: How to Review a Manuscript from an Editor's Perspective?. Journal of Gastrointestinal Surgery, 2020, 24, 1452-1454.	1.7	1
254	Introducing Research Communications to the Journal of Gastrointestinal Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 973.	1.7	0
255	Surgical management of pancreatic neuroendocrine liver metastases. Journal of Gastrointestinal Oncology, 2020, 11, 590-600.	1.4	19
256	Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2020, 230, 381-391e2.	0.5	31
257	Assessing post-discharge costs of hepatopancreatic surgery: an evaluation of Medicare expenditure. Surgery, 2020, 167, 978-984.	1.9	10
258	Introduction. Journal of Gastrointestinal Surgery, 2020, 24, 1231.	1.7	0
259	Assessment of utilization efficiency using machine learning techniques: A study of heterogeneity in preoperative healthcare utilization among super-utilizers. American Journal of Surgery, 2020, 220, 714-720.	1.8	15
260	Accessing surgical care for esophageal cancer: patient travel patterns to reach higher volume center. Ecological Management and Restoration, 2020, 33, .	0.4	12
261	Dedicated Cancer Centers are More Likely to Achieve a Textbook Outcome Following Hepatopancreatic Surgery. Annals of Surgical Oncology, 2020, 27, 1889-1897.	1.5	41
262	Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. Journal of Surgical Oncology, 2020, 121, 936-944.	1.7	56
263	Does spiritual and religious orientation impact the clinical practice of healthcare providers?. Journal of Interprofessional Care, 2020, 34, 520-527.	1.7	7
264	Current state of the art imaging approaches for colorectal liver metastasis. Hepatobiliary Surgery and Nutrition, 2020, 9, 35-48.	1.5	23
265	Redesigning a Department of Surgery during the COVID-19 Pandemic. Journal of Gastrointestinal Surgery, 2020, 24, 1852-1859.	1.7	22
266	Minimally Invasive Versus Open Liver Resection for Hepatocellular Carcinoma in the Setting of Portal Vein Hypertension: Results of an International Multi-institutional Analysis. Annals of Surgical Oncology, 2020, 27, 3360-3371.	1.5	19
267	The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1667-1674.	0.3	37
268	Assessing Differences in Cancer Surgeon Approaches to Patient-Centered Decision-Making Using Vignette-Based Methodology. Annals of Surgical Oncology, 2020, 27, 2149-2156.	1.5	2
269	Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Annals of Surgical Oncology, 2020, 27, 2321-2331.	1.5	76
270	Influence of hospital teaching status on the chance to achieve a textbook outcome after hepatopancreatic surgery for cancer among Medicare beneficiaries. Surgery, 2020, 168, 92-100.	1.9	54

#	Article	IF	CITATIONS
271	Rural Surgery and Status of the Rural Workplace. Surgical Clinics of North America, 2020, 100, 835-847.	1.5	21
272	Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. Expert Opinion on Investigational Drugs, 2020, 29, 107-110.	4.1	7
273	Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. Annals of Surgical Oncology, 2020, 27, 3717-3726.	1.5	4
274	A novel online calculator based on albumin-bilirubin and aspartate transaminase-to-platelet ratio index for predicting postoperative morbidity following hepatectomy for hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1591-1591.	1.7	4
275	Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World Journal of Gastrointestinal Surgery, 2020, 12, 159-170.	1.5	7
276	Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors. Surgical Oncology Clinics of North America, 2020, 29, xiii-xiv.	1.5	0
277	ASO Author Reflections: Advances in the Multidisciplinary Management of Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2866-2867.	1.5	2
278	Management of Melanoma. Surgical Oncology Clinics of North America, 2020, 29, xiii-xiv.	1.5	0
279	A novel online calculator to predict perioperative blood transfusion in patients undergoing liver resection for hepatocellular carcinoma: an international multicenter study. Hpb, 2020, 22, 1711-1721.	0.3	5
280	Liver Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 227-241.	1.6	8
281	Treatment of neuroendocrine liver metastases: a patent landscape review. Pharmaceutical Patent Analyst, 2020, 9, 29-32.	1.1	0
282	Long-term outcomes after curative resection of HCV-positive versus non-hepatitis related hepatocellular carcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1549-1556.	0.3	0
283	Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A populationâ€based analysis. Journal of Surgical Oncology, 2019, 119, 278-287.	1.7	30
284	Prognosis and Adherence with the National Comprehensive Cancer Network Guidelines of Patients with Biliary Tract Cancers: an Analysis of the National Cancer Database. Journal of Gastrointestinal Surgery, 2019, 23, 518-528.	1.7	12
285	Current Approaches in the Management of Hepatic Adenomas. Journal of Gastrointestinal Surgery, 2019, 23, 199-209.	1.7	21
286	Time to Readmission and Mortality Among Patients Undergoing Liver and Pancreatic Surgery. World Journal of Surgery, 2019, 43, 242-251.	1.6	6
287	The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. Journal of Gastrointestinal Surgery, 2019, 23, 484-491.	1.7	12
288	Hospice utilization among Medicare beneficiaries dying from pancreatic cancer. Journal of Surgical Oncology, 2019, 120, 624-631.	1.7	19

#	Article	IF	CITATIONS
289	Discordance in prediction of prognosis among patients with intrahepatic cholangiocarcinoma: A preoperative vs postoperative perspective. Journal of Surgical Oncology, 2019, 120, 946-955.	1.7	6
290	Novel Machine Learning Approach to Identify Preoperative Risk Factors Associated With Super-Utilization of Medicare Expenditure Following Surgery. JAMA Surgery, 2019, 154, 1014.	4.3	32
291	Data resource profile: State Inpatient Databases. International Journal of Epidemiology, 2019, 48, 1742-1742h.	1.9	10
292	The Impact of Dedicated Cancer Centers on Outcomes Among Medicare Beneficiaries Undergoing Liver and Pancreatic Cancer Surgery. Annals of Surgical Oncology, 2019, 26, 4083-4090.	1.5	18
293	Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?. Hpb, 2019, 21, 1648-1655.	0.3	10
294	Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery, 2019, 166, 983-990.	1.9	54
295	Immunotherapy for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, xiii-xiv.	1.5	Ο
296	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors â‰û cm after curative resection: A multiâ€institutional study of 392 cases. Journal of Surgical Oncology, 2019, 120, 1071-1079.	1.7	47
297	Potential survival benefit of radiofrequency ablation for small solitary intrahepatic cholangiocarcinoma in nonsurgically managed patients: A populationâ€based analysis. Journal of Surgical Oncology, 2019, 120, 1358-1364.	1.7	21
298	Accessing surgical care for pancreaticoduodenectomy: Patient variation in travel distance and choice to bypass hospitals to reach higher volume centers. Journal of Surgical Oncology, 2019, 120, 1318-1326.	1.7	27
299	A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. Clinical Chemistry, 2019, 65, 1543-1553.	3.2	53
300	Understanding the use of attachment theory applied to the patient-provider relationship in cancer care: Recommendations for future research and clinical practice. Surgical Oncology, 2019, 31, 101-110.	1.6	14
301	Conditional diseaseâ€free survival after curativeâ€intent liver resection for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2019, 120, 1087-1095.	1.7	10
302	Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. Surgery, 2019, 166, 967-974.	1.9	45
303	Treatment strategies for neuroendocrine liver metastases: an update. Expert Opinion on Orphan Drugs, 2019, 7, 327-335.	0.8	4
304	Association of Depression Risk with Patient Experience, Healthcare Expenditure, and Health Resource Utilization Among Adults with Atherosclerotic Cardiovascular Disease. Journal of General Internal Medicine, 2019, 34, 2427-2434.	2.6	15
305	Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10Âcm): a multicenter propensity matching analysis. Hepatology International, 2019, 13, 736-747.	4.2	51
306	Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review. Surgical Oncology, 2019, 31, 83-89.	1.6	22

#	Article	IF	CITATIONS
307	Potential disease burden of patients with substance abuse undergoing major abdominal surgery: A propensity score-matched analysis. Surgery, 2019, 166, 1181-1187.	1.9	4
308	Local referrals as a strategy for increasing value of surgical care among medicare patients undergoing liver and pancreatic surgery. Hpb, 2019, 21, 1552-1562.	0.3	5
309	Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study. European Journal of Surgical Oncology, 2019, 45, 2360-2368.	1.0	10
310	Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. Journal of Gastrointestinal Surgery, 2019, 23, 1044-1054.	1.7	39
311	Impact of skilled nursing facility quality on postoperative outcomes after pancreatic surgery. Surgery, 2019, 166, 1-7.	1.9	23
312	Use of perioperative epidural analgesia among Medicare patients undergoing hepatic and pancreatic surgery. Hpb, 2019, 21, 1064-1071.	0.3	11
313	Complications after liver surgery: a benchmark analysis. Hpb, 2019, 21, 1139-1149.	0.3	47
314	Assessing structure and characteristics of social networks among cancer survivors: impact on general health. Supportive Care in Cancer, 2019, 27, 3045-3051.	2.2	12
315	Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight, 2019, 4, .	5.0	131
316	Financial toxicity risk among adult patients undergoing cancer surgery in the United States: An analysis of the National Inpatient Sample. Journal of Surgical Oncology, 2019, 120, 397-406.	1.7	33
317	Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?. Annals of Surgical Oncology, 2019, 26, 2959-2968.	1.5	43
318	Outcomes After Resection of Hepatocellular Carcinoma: Intersection of Travel Distance and Hospital Volume. Journal of Gastrointestinal Surgery, 2019, 23, 1425-1434.	1.7	22
319	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2019, 154, e190571.	4.3	149
320	Prognostic utility of albuminâ€bilirubin grade for short―and longâ€ŧerm outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multiâ€institutional analysis of 706 patients. Journal of Surgical Oncology, 2019, 120, 206-213.	1.7	39
321	A novel online prognostic tool to predict longâ€ŧerm survival after liver resection for intrahepatic cholangiocarcinoma: The "metroâ€ŧicket―paradigm. Journal of Surgical Oncology, 2019, 120, 223-230.	1.7	26
322	Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 2549-2557.	1.5	74
323	Impact of Neoadjuvant Chemotherapy on the Postoperative Outcomes of Patients Undergoing Liver Resection for Colorectal Liver Metastases: A Population-Based Propensity-Matched Analysis. Journal of the American College of Surgeons, 2019, 229, 69-77e2.	0.5	25
324	A national assessment of the utilization, quality and cost of laparoscopic liver resection. Hpb, 2019, 21, 1327-1335.	0.3	8

#	ARTICLE	IF	CITATIONS
325	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2019, 26, 1814-1823.	1.5	19
326	Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases. Hpb, 2019, 21, 1230-1239.	0.3	14
327	Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2019, 26, 1657-1668.	1.5	50
328	Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. World Journal of Surgery, 2019, 43, 1777-1787.	1.6	126
329	Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 1841-1850.	1.5	51
330	Geographic Distribution of Adult Inpatient Surgery Capability in the USA. Journal of Gastrointestinal Surgery, 2019, 23, 1652-1660.	1.7	18
331	Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. European Journal of Surgical Oncology, 2019, 45, 1084-1091.	1.0	13
332	Association of Income Disparities with Patient-Reported Healthcare Experience. Journal of General Internal Medicine, 2019, 34, 884-892.	2.6	37
333	Variation in the cost-of-rescue among medicare patients with complications following hepatopancreatic surgery. Hpb, 2019, 21, 310-318.	0.3	22
334	Hot spotting surgical patients undergoing hepatopancreatic procedures. Hpb, 2019, 21, 765-772.	0.3	12
335	Predictors and outcomes of nonroutine discharge after hepatopancreatic surgery. Surgery, 2019, 165, 1128-1135.	1.9	11
336	Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?. Annals of Surgical Oncology, 2019, 26, 2242-2250.	1.5	27
337	Association of family history with long-term prognosis in patients undergoing liver resection of HBV-related hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 88-100.	1.5	10
338	Impact of Liver Cirrhosis on Perioperative Outcomes Among Elderly Patients Undergoing Hepatectomy: the Effect of Minimally Invasive Surgery. Journal of Gastrointestinal Surgery, 2019, 23, 2346-2353.	1.7	15
339	Association Between Travel Distance, Hospital Volume, and Outcomes Following Resection of Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 944-952.	1.7	24
340	Patient preferences on the use of technology in cancer surveillance after curative surgery: A cross-sectional analysis. Surgery, 2019, 165, 782-788.	1.9	12
341	Intrahepatic Cholangiocarcinoma. Surgical Oncology Clinics of North America, 2019, 28, 587-599.	1.5	110
342	Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, xiii-xiv.	1.5	0

#	Article	IF	CITATIONS
343	Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma. Hpb, 2019, 21, 981-989.	0.3	38
344	Characterizing and Assessing the Impact of Surgery on Healthcare Spending Among Medicare Enrolled Preoperative Super-utilizers. Annals of Surgery, 2019, 270, 554-563.	4.2	29
345	Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study. Oncologist, 2019, 24, e730-e739.	3.7	8
346	Understanding patient expectations around therapeutic benefits, risks, and the chance of cure. American Journal of Surgery, 2019, 217, 410-412.	1.8	7
347	Readmission after pancreatic resection: causes, costs and cost-effectiveness analysis of high versus low quality hospitals using the Nationwide Readmission Database. Hpb, 2019, 21, 291-300.	0.3	10
348	Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report. Advances in Radiation Oncology, 2019, 4, 10-14.	1.2	1
349	Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. European Journal of Surgical Oncology, 2019, 45, 800-807.	1.0	12
350	Routine intensive care unit admission among patients undergoing major pancreatic surgery for cancer: No effect on failure to rescue. Surgery, 2019, 165, 741-746.	1.9	18
351	Staging laparoscopy among three subtypes of extraâ€hepatic biliary malignancy: a 15â€year experience from 10 institutions. Journal of Surgical Oncology, 2019, 119, 288-294.	1.7	12
352	A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery, 2019, 165, 721-730.	1.9	66
353	Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review. Journal of Surgical Oncology, 2019, 119, 30-39.	1.7	40
354	Perioperative use of blood products is associated with risk of morbidity and mortality after surgery. American Journal of Surgery, 2019, 218, 62-70.	1.8	14
355	Postoperative Pancreatic Fistula Following Pancreaticoduodenectomy—Stratification of Patient Risk. Journal of Gastrointestinal Surgery, 2019, 23, 1817-1824.	1.7	25
356	Impact of microvascular invasion on clinical outcomes after curativeâ€intent resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2019, 119, 21-29.	1.7	33
357	The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Review of Clinical Pharmacology, 2019, 12, 101-108.	3.1	12
358	Minimally Invasive Oncologic Surgery. Surgical Oncology Clinics of North America, 2019, 28, xiii-xiv.	1.5	2
359	Population level outcomes and costs of single stage colon and liver resection versus conventional two-stage approach for the resection of metastatic colorectal cancer. Hpb, 2019, 21, 456-464.	0.3	15
360	Index versus Non-index Readmission After Hepato-Pancreato-Biliary Surgery: Where Do Patients Go to Be Readmitted?. Journal of Gastrointestinal Surgery, 2019, 23, 702-711.	1.7	25

#	Article	IF	CITATIONS
361	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery, 2019, 165, 657-663.	1.9	16
362	Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 611-618.	1.5	34
363	Procedure‧pecific Volume and Nurseâ€ŧoâ€Patient Ratio: Implications for Failure to Rescue Patients Following Liver Surgery. World Journal of Surgery, 2019, 43, 910-919.	1.6	26
364	Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Research, 2019, 234, 103-109.	1.6	15
365	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. Surgery, 2019, 165, 548-556.	1.9	39
366	Patterns of readmission among the elderly after hepatopancreatobiliary surgery. American Journal of Surgery, 2019, 217, 413-416.	1.8	10
367	Cost of Major Complications After Liver Resection in the United States. Annals of Surgery, 2019, 269, 503-510.	4.2	35
368	Implementation of a Blood Management Program at a Tertiary Care Hospital. Annals of Surgery, 2019, 269, 1073-1079.	4.2	43
369	Coaxial projective imaging system for surgical navigation and telementoring. Journal of Biomedical Optics, 2019, 24, 1.	2.6	7
370	Handheld projective imaging device for near-infrared fluorescence imaging and intraoperative guidance of sentinel lymph node resection. Journal of Biomedical Optics, 2019, 24, 1.	2.6	10
371	Resection margin distance in extrahepatic cholangiocarcinoma: How much is enough?. Journal of Clinical Oncology, 2019, 37, 455-455.	1.6	0
372	Minimally Invasive Oncologic Surgery, Part II. Surgical Oncology Clinics of North America, 2019, 28, xiii-xiv.	1.5	1
373	Racial/ethnic disparities in hospice utilization among Medicare beneficiaries dying from pancreatic cancer Journal of Clinical Oncology, 2019, 37, 41-41.	1.6	0
374	Liver transplantation in patients with liver metastases from neuroendocrine tumors. Minerva Chirurgica, 2019, 74, 399-406.	0.8	7
375	Safety and oncologic outcomes of robotic liver resections: A systematic review. Journal of Surgical Oncology, 2018, 117, 1517-1530.	1.7	59
376	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2018, 25, 1140-1149.	1.5	48
377	Postoperative low hepatitis C virus load predicts longâ€ŧerm outcomes after hepatectomy for hepatocellular carcinoma. Journal of Surgical Oncology, 2018, 117, 902-911.	1.7	4
378	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	1.5	15

#	Article	IF	CITATIONS
379	Minimally invasive versus open surgery in the Medicare population: a comparison of post-operative and economic outcomes. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 3874-3880.	2.4	21
380	Development and prospective validation of a model estimating risk of readmission in cancer patients. Journal of Surgical Oncology, 2018, 117, 1113-1118.	1.7	6
381	Practical Guide to Surgical Data Sets: National Surgical Quality Improvement Program (NSQIP) and Pediatric NSQIP. JAMA Surgery, 2018, 153, 764.	4.3	117
382	Diagnostic and therapeutic implications of novel peptides in hepatocellular carcinoma. Hepatology, 2018, 68, 1223-1225.	7.3	0
383	Impact of histological subtype on the prognosis of patients undergoing surgery for colon cancer. Journal of Surgical Oncology, 2018, 117, 1355-1363.	1.7	26
384	The Prognostic Value of Varying Definitions of Positive Resection Margin in Patients with Colorectal Cancer Liver Metastases. Journal of Gastrointestinal Surgery, 2018, 22, 1350-1357.	1.7	15
385	Nomogram predicting the risk of recurrence after curativeâ€intent resection of primary nonâ€metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2018, 117, 868-878.	1.7	36
386	Prognostic significance of poorly differentiated clusters and tumor budding in colorectal liver metastases. Journal of Surgical Oncology, 2018, 117, 1364-1375.	1.7	26
387	Association of shared decision-making on patient-reported health outcomes and healthcare utilization. American Journal of Surgery, 2018, 216, 7-12.	1.8	140
388	Minimally invasive hepatopancreatobiliary surgery: Where do we go from here?. Surgical Oncology, 2018, 27, A2-A4.	1.6	3
389	Is BMI associated with postâ€operative complication risk among patients undergoing major abdominal surgery for cancer? A systematic review. Journal of Surgical Oncology, 2018, 117, 1009-1019.	1.7	12
390	The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2018, 22, 477-485.	1.7	16
391	Steps to Getting Your Manuscript Published in a High-Quality Medical Journal. Annals of Surgical Oncology, 2018, 25, 850-855.	1.5	17
392	Lymphadenectomy for Intrahepatic Cholangiocarcinoma: Has Nodal Evaluation Been Increasingly Adopted by Surgeons over Time?A National Database Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 668-675.	1.7	55
393	Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2018, 226, 393-403.	0.5	37
394	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. Hpb, 2018, 20, 332-339.	0.3	27
395	Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multiâ€institution analysis from the U.S. extrahepatic biliary malignancy consortium. Journal of Surgical Oncology, 2018, 117, 363-371.	1.7	36
396	The impact of the aging population and incidence of cancer on future projections of general surgical workforce needs. Surgery, 2018, 163, 553-559.	1.9	43

#	Article	IF	CITATIONS
397	Laparoscopic Versus Open Adrenalectomy for Localized/Locally Advanced Primary Adrenocortical Carcinoma (ENSAT l–III) in Adults: Is Margin-Free Resection the Key Surgical Factor that Dictates Outcome? A Review of the Literature. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2018, 28, 408-414.	1.0	32
398	The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery, 2018, 163, 726-731.	1.9	29
399	Circulating monocyte chemoattractant proteinâ€l (MCPâ€l) is associated with cachexia in treatmentâ€naÃ⁻ve pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 358-368.	7.3	73
400	Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Periâ€Operative Outcomes. World Journal of Surgery, 2018, 42, 2551-2560.	1.6	47
401	Which Patients Require Extended Thromboprophylaxis After Colectomy? Modeling Risk and Assessing Indications for Postâ€discharge Pharmacoprophylaxis. World Journal of Surgery, 2018, 42, 2242-2251.	1.6	23
402	Reply to "Poorly differentiated clusters in colorectal liver metastases: Prognostic significance in synchronous and metachronous metastases― Journal of Surgical Oncology, 2018, 117, 1858-1859.	1.7	0
403	Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC. Journal of Gastrointestinal Surgery, 2018, 22, 1576-1584.	1.7	13
404	Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. Journal of Surgical Oncology, 2018, 117, 1260-1266.	1.7	11
405	Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2018, 44, 927-938.	1.0	97
406	Impact of Post-Discharge Disposition on Risk and Causes of Readmission Following Liver and Pancreas Surgery. Journal of Gastrointestinal Surgery, 2018, 22, 1221-1229.	1.7	20
407	Hospital Teaching Status and Medicare Expenditures for Hepatoâ€Pancreatoâ€Biliary Surgery. World Journal of Surgery, 2018, 42, 2969-2979.	1.6	30
408	Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. Journal of Gastrointestinal Surgery, 2018, 22, 52-59.	1.7	92
409	Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. Annals of Surgery, 2018, 267, 544-551.	4.2	14
410	Timing of Surgical Resection for Curative Colorectal Cancer with Liver Metastasis. Annals of Surgical Oncology, 2018, 25, 32-37.	1.5	28
411	Ottawa Criteria for Appropriate Transfusions in Hepatectomy. Annals of Surgery, 2018, 267, 766-774.	4.2	21
412	The Tumor Burden Score. Annals of Surgery, 2018, 267, 132-141.	4.2	264
413	Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. Hpb, 2018, 20, 277-284.	0.3	39
414	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 486-489.	0.8	2

#	Article	IF	CITATIONS
415	Transplantation Versus Resection for Hilar Cholangiocarcinoma. Annals of Surgery, 2018, 267, 797-805.	4.2	137
416	Timing of disease occurrence and hepatic resection on longâ€ŧerm outcome of patients with neuroendocrine liver metastasis. Journal of Surgical Oncology, 2018, 117, 171-181.	1.7	16
417	Pathological factors and prognosis of resected liver metastases of colorectal carcinoma: implications and proposal for a pathological reporting protocol. Histopathology, 2018, 72, 377-390.	2.9	28
418	Assessing the Non-tumorous Liver: Implications for Patient Management and Surgical Therapy. Journal of Gastrointestinal Surgery, 2018, 22, 344-360.	1.7	3
419	Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curativeâ€Intent Resection: a Multiâ€Institutional Study. World Journal of Surgery, 2018, 42, 849-857.	1.6	17
420	Cohort Contributions to Race―and Gender‧pecific Trends in the Incidence of Hepatocellular Carcinoma in the USA. World Journal of Surgery, 2018, 42, 835-840.	1.6	16
421	Colon Cancer. Surgical Oncology Clinics of North America, 2018, 27, xiii-xiv.	1.5	7
422	Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. Journal of Surgical Oncology, 2018, 117, 1267-1277.	1.7	32
423	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Annals of Surgical Oncology, 2018, 25, 280-289.	1.5	31
424	Updates and Critical Insights on Glissonian Approach in Liver Surgery. Journal of Gastrointestinal Surgery, 2018, 22, 154-163.	1.7	18
425	Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review. Journal of Surgical Oncology, 2018, 117, 341-353.	1.7	61
426	Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. Journal of Hepatology, 2018, 68, 655-662.	3.7	36
427	Impact of Surgical Margin Width on Recurrence and Overall Survival Following RO Hepatic Resection of Colorectal Metastases. Annals of Surgery, 2018, 267, 1047-1055.	4.2	102
428	Innovation in the Diagnosis and Management of Breast Cancer. Surgical Oncology Clinics of North America, 2018, 27, xiii-xiv.	1.5	1
429	Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two‣tage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Metaâ€Analysis. World Journal of Surgery, 2018, 42. 806-815.	1.6	107
430	Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. Journal of Clinical and Translational Hepatology, 2018, 6, 1-8.	1.4	49
431	Adjuvant Therapy for Biliary Tract Cancers: New Evidence to Resolve Old Questions. Journal of Oncology Practice, 2018, 14, 723-724.	2.5	8
432	Role of associating liver partition and portal vein ligation in staged hepatectomy (ALPPS)—strategy for colorectal liver metastases. Translational Gastroenterology and Hepatology, 2018, 3, 66-66.	3.0	10

#	Article	IF	CITATIONS
433	Implementation and early outcomes for a surgeonâ€directed hepatic arterial infusion pump program for colorectal liver metastases. Journal of Surgical Oncology, 2018, 118, 1065-1073.	1.7	9
434	The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis. Journal of Surgical Oncology, 2018, 118, 1074-1080.	1.7	2
435	Early recurrence of wellâ€differentiated (G1) neuroendocrine liver metastasis after curativeâ€intent surgery: Risk factors and outcome. Journal of Surgical Oncology, 2018, 118, 1096-1104.	1.7	8
436	Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and metaâ€analysis. Journal of Surgical Oncology, 2018, 118, 477-485.	1.7	31
437	Do psoas muscle area and volume correlate with postoperative complications in patients undergoing rectal cancer resection?. American Journal of Surgery, 2018, 215, 503-506.	1.8	22
438	Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?. Annals of Surgical Oncology, 2018, 25, 3928-3935.	1.5	19
439	Three Common Methodological Issues in Studies of Surgical Readmission Rates. JAMA Surgery, 2018, 153, 1074.	4.3	16
440	Ten-year reassessment of the shortage of general surgeons: Increases in graduation numbers of general surgery residents are insufficient to meet the future demand for general surgeons. Surgery, 2018, 164, 726-732.	1.9	67
441	<i>Accuracy of the ACS NSQIP Online Risk Calculator Depends on How You Look at It: Results from the United States Gastric Cancer Collaborative</i> . American Surgeon, 2018, 84, 358-364.	0.8	11
442	Hydroxylase Activity of ASPH Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-to-Mesenchymal Transition Pathway. EBioMedicine, 2018, 31, 287-298.	6.1	38
443	Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers. Journal of Gastrointestinal Surgery, 2018, 22, 1697-1708.	1.7	50
444	Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10â€institution study from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2018, 117, 1638-1647.	1.7	10
445	Emerging treatment options for cholangiocarcinoma. Expert Opinion on Orphan Drugs, 2018, 6, 527-536.	0.8	3
446	Peritoneal Malignancies. Surgical Oncology Clinics of North America, 2018, 27, xiii-xiv.	1.5	0
447	Perioperative complications and the cost of rescue or failure to rescue in hepato-pancreato-biliary surgery. Hpb, 2018, 20, 854-864.	0.3	33
448	The impact of a malignant diagnosis on the pattern and outcome of readmission after liver and pancreatic surgery: An analysis of the nationwide readmissions database. Journal of Surgical Oncology, 2018, 117, 1624-1637.	1.7	6
449	Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus–Related Hepatocellular Carcinoma. JAMA Surgery, 2018, 153, e182721.	4.3	74
450	Quality in a Shifting Payment Landscape and the Implications for Surgical Oncology. Surgical Oncology Clinics of North America, 2018, 27, xiii-xiv.	1.5	2

#	Article	IF	CITATIONS
451	The Cost of Complications Following Major Resection of Malignant Neoplasia. Journal of Gastrointestinal Surgery, 2018, 22, 1976-1986.	1.7	13
452	Specific Medicare Severity-Diagnosis Related Group Codes Increase the Predictability of 30-Day Unplanned Hospital Readmission After Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2018, 22, 1920-1927.	1.7	3
453	A Comparison of Open and Minimally Invasive Surgery for Hepatic and Pancreatic Resections Among the Medicare Population. Journal of Gastrointestinal Surgery, 2018, 22, 2088-2096.	1.7	19
454	Variation in Medicare Payments and Reimbursement Rates for Hepatopancreatic Surgery Based on Quality: Is There a Financial Incentive for High-Quality Hospitals?. Journal of the American College of Surgeons, 2018, 227, 212-222e2.	0.5	8
455	An advance care plan decision support video before major surgery: a patient- and family-centred approach. BMJ Supportive and Palliative Care, 2018, 8, 229-236.	1.6	8
456	Surgical approaches for the treatment of perihilar cholangiocarcinoma. Expert Review of Anticancer Therapy, 2018, 18, 673-683.	2.4	9
457	The Impact of Discharge Timing on Readmission Following Hepatopancreatobiliary Surgery: a Nationwide Readmission Database Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 1538-1548.	1.7	14
458	Practices and Perceptions Among Surgical Oncologists in the Perioperative Care of Obese Cancer Patients. Annals of Surgical Oncology, 2018, 25, 2513-2519.	1.5	7
459	The relationship of hospital market concentration, costs, and quality for major surgical procedures. American Journal of Surgery, 2018, 216, 1037-1045.	1.8	2
460	The Cost of Failure: Assessing the Cost-Effectiveness of Rescuing Patients from Major Complications After Liver Resection Using the National Inpatient Sample. Journal of Gastrointestinal Surgery, 2018, 22, 1688-1696.	1.7	17
461	Minimally Invasive Versus Open Primary Resection for Retroperitoneal Soft Tissue Sarcoma: A Propensity-Matched Study From the National Cancer Database. Annals of Surgical Oncology, 2018, 25, 2209-2217.	1.5	13
462	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2018, 25, 2308-2315.	1.5	19
463	Outcomes of Surgical and Endoscopic Resection of Duodenal Neuroendocrine Tumours (NETs): a Systematic Review of the Literature. Journal of Gastrointestinal Surgery, 2018, 22, 1652-1658.	1.7	17
464	Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 956-965.	0.3	28
465	The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery, 2018, 164, 411-418.	1.9	38
466	Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2018, 12, 671-681.	3.0	45
467	Synergistic Effects of Perioperative Complications on 30-Day Mortality Following Hepatopancreatic Surgery. Journal of Gastrointestinal Surgery, 2018, 22, 1715-1723.	1.7	18
468	Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection. Journal of Surgical Oncology, 2018, 118, 422-430.	1.7	33

#	Article	IF	CITATIONS
469	Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B?. Annals of Translational Medicine, 2018, 6, 397-397.	1.7	3
470	Effect of Increased Intra-abdominal Pressure on Liver Histology and Hemodynamics: An Experimental Study. In Vivo, 2018, 32, 85-91.	1.3	3
471	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	0
472	Accuracy of the ACS NSQIP Online Risk Calculator Depends on How You Look at It: Results from the United States Gastric Cancer Collaborative. American Surgeon, 2018, 84, 358-364.	0.8	7
473	Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology, 2017, 27, 526-535.	4.5	54
474	Curative Surgical Resection of Adrenocortical Carcinoma. Annals of Surgery, 2017, 265, 197-204.	4.2	38
475	Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients. Journal of Gastrointestinal Surgery, 2017, 21, 487-495.	1.7	21
476	Discharge decision-making after complex surgery: Surgeon behaviors compared to predictive modeling to reduce surgical readmissions. American Journal of Surgery, 2017, 213, 112-119.	1.8	13
477	Neuroendocrine liver metastasis: The chance to be cured after liver surgery. Journal of Surgical Oncology, 2017, 115, 687-695.	1.7	35
478	Prognostic impact of complications after resection of early stage hepatocellular carcinoma. Journal of Surgical Oncology, 2017, 115, 791-804.	1.7	53
479	The impact of perioperative red blood cell transfusions in patients undergoing liver resection: a systematic review. Hpb, 2017, 19, 321-330.	0.3	70
480	Frailty as a Risk Predictor of Morbidity and Mortality Following Liver Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 822-830.	1.7	65
481	Routine portâ€site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multiâ€institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2017, 115, 805-811.	1.7	28
482	The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients—A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 115, 312-318.	1.7	46
483	Postoperative complications following intraoperative radiotherapy in abdominopelvic malignancy: A single institution analysis of 113 consecutive patients. Journal of Surgical Oncology, 2017, 115, 883-890.	1.7	5
484	Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surgical Oncology, 2017, 26, 125-137.	1.6	99
485	Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 116, 133-139.	1.7	57
486	Updates in hepatic oncology imaging. Surgical Oncology, 2017, 26, 195-206.	1.6	14

#	Article	IF	CITATIONS
487	Regret in Surgical Decision Making: A Systematic Review of Patient and Physician Perspectives. World Journal of Surgery, 2017, 41, 1454-1465.	1.6	87
488	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. Journal of Gastrointestinal Surgery, 2017, 21, 1245-1253.	1.7	30
489	Impact of Morphological Status on Long-Term Outcome Among Patients Undergoing Liver Surgery for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2017, 24, 2491-2501.	1.5	31
490	Liver transplantation for unresectable colorectal liver metastases: A systematic review. Journal of Surgical Oncology, 2017, 116, 288-297.	1.7	56
491	Risk factors and prediction model for inpatient surgical site infection after major abdominal surgery. Journal of Surgical Research, 2017, 217, 153-159.	1.6	58
492	Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 116, 298-306.	1.7	39
493	The prognostic utility of the "Tumor Burden Score―based on preoperative radiographic features of colorectal liver metastases. Journal of Surgical Oncology, 2017, 116, 515-523.	1.7	45
494	Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery, 2017, 162, 285-294.	1.9	25
495	Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis. Journal of Surgical Oncology, 2017, 116, 643-650.	1.7	80
496	Pediatric choledochal cysts: diagnosis and current management. Pediatric Surgery International, 2017, 33, 637-650.	1.4	100
497	Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. JAMA Surgery, 2017, 152, e165059.	4.3	81
498	Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. Journal of the American College of Surgeons, 2017, 224, 406-413.	0.5	28
499	Factors associated with decisional regret among patients undergoing major thoracic and abdominal operations. Surgery, 2017, 161, 1058-1066.	1.9	35
500	Update on current problems in colorectal liver metastasis. Current Problems in Surgery, 2017, 54, 554-602.	1.1	39
501	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	10.7	153
502	Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2017, 19, 1104-1111.	0.3	25
503	Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1984-1992.	1.7	11
504	The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. Journal of Gastrointestinal Surgery, 2017, 21, 2016-2024.	1.7	20

#	Article	IF	CITATIONS
505	Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2017, 21, 1888-1897.	1.7	31
506	Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. Journal of Gastrointestinal Surgery, 2017, 21, 1813-1820.	1.7	12
507	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 7333-7339.	7.0	128
508	Performance of prognostic scores and staging systems in predicting longâ€ŧerm survival outcomes after surgery for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2017, 116, 1085-1095.	1.7	42
509	Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. Hpb, 2017, 19, 901-909.	0.3	74
510	Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment. Journal of Gastrointestinal Surgery, 2017, 21, 1821-1830.	1.7	24
511	Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases. Journal of Surgical Oncology, 2017, 116, 1150-1158.	1.7	7
512	Survival after resection of perihilar cholangiocarcinoma inÂpatients with lymph node metastases. Hpb, 2017, 19, 735-740.	0.3	27
513	Increased kinetic growth rate during late phase liver regeneration impacts the risk of tumor recurrence after colorectal liver metastases resection. Hpb, 2017, 19, 808-817.	0.3	7
514	Association of Hospital Market Concentration With Costs of Complex Hepatopancreaticobiliary Surgery. JAMA Surgery, 2017, 152, e172158.	4.3	26
515	Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 2039-2047.	1.7	23
516	Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. Journal of Gastrointestinal Surgery, 2017, 21, 1841-1850.	1.7	65
517	Trends in the Mortality of Hepatocellular Carcinoma in the United States. Journal of Gastrointestinal Surgery, 2017, 21, 2033-2038.	1.7	53
518	Effect of surgeon "experience―with laparoscopy on postoperative outcomes after colorectal surgery. Surgery, 2017, 162, 880-890.	1.9	14
519	The impact of extrahepatic disease among patients undergoing liverâ€directed therapy for neuroendocrine liver metastasis. Journal of Surgical Oncology, 2017, 116, 841-847.	1.7	15
520	The Prognostic Impact of Determining Resection Margin Status for Multiple Colorectal Metastases According to the Margin of the Largest Lesion. Annals of Surgical Oncology, 2017, 24, 2438-2446.	1.5	19
521	Postoperative Abdominal Adhesions: Clinical Significance and Advances in Prevention and Management. Journal of Gastrointestinal Surgery, 2017, 21, 1713-1722.	1.7	99
522	Hospital Volume and the Costs Associated with Surgery for Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1411-1419.	1.7	36

#	Article	IF	CITATIONS
523	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2017, 24, 1343-1350.	1.5	68
524	Use of the Modified Frailty Index in the American College of Surgeons National Surgical Improvement Program Database. JAMA Surgery, 2017, 152, 205.	4.3	58
525	Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival. JAMA Surgery, 2017, 152, 143.	4.3	74
526	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. Journal of Gastrointestinal Surgery, 2017, 21, 352-362.	1.7	27
527	Evaluating Trends in the Volume-Outcomes Relationship Following Liver Surgery: Does Regionalization Benefit All Patients the Same?. Journal of Gastrointestinal Surgery, 2017, 21, 463-471.	1.7	37
528	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World Journal of Surgery, 2017, 41, 224-231.	1.6	19
529	Variations in hospitals costs for surgical procedures: inefficient care or sick patients?. American Journal of Surgery, 2017, 213, 1-9.	1.8	28
530	The price of surgery: markup of operative procedures in the United States. Journal of Surgical Research, 2017, 208, 192-197.	1.6	16
531	KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2017, 24, 264-271.	1.5	68
532	Perioperative Hyperglycemia and Postoperative Outcomes in Patients Undergoing Resection of Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2017, 21, 228-237.	1.7	11
533	Albumin-Bilirubin Score: Predicting Short-Term Outcomes Including Bile Leak and Post-hepatectomy Liver Failure Following Hepatic Resection. Journal of Gastrointestinal Surgery, 2017, 21, 238-248.	1.7	81
534	A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal versus Gastric Staging System for Gastroesophageal Junction Cancer in a Western Population. American Surgeon, 2017, 83, 82-89.	0.8	2
535	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon, 2017, 83, 679-686.	0.8	44
536	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. American Surgeon, 2017, 83, 761-768.	0.8	12
537	Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2017, 6, 67-78.	1.5	53
538	Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2017, 6, 35-43.	1.5	34
539	Intrahepatic cholangiocarcinoma: from diagnosis to treatment. Hepatobiliary Surgery and Nutrition, 2017, 6, 1-1.	1.5	9
540	Laparoscopic hepatectomy for hepatocellular carcinoma: are oncologic outcomes truly superior to an open approach?. Hepatobiliary Surgery and Nutrition, 2017, ï¼–, 200-202.	1.5	5

#	Article	IF	CITATIONS
541	Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival. Hepatobiliary Surgery and Nutrition, 2017, ï¼–, 144-153.	1.5	6
542	Histologic classification and grading enhances gallbladder cancer staging: A population-based prognostic score validated by the U.S. Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2017, 35, 356-356.	1.6	2
543	Current Management of Perihilar Cholangiocarcinoma and Future Perspectives. Chirurgia (Romania), 2017, 112, 193.	0.5	32
544	Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes. Anticancer Research, 2017, 37, 9-14.	1.1	88
545	Solid Pseudopapillary Tumor of the Pancreas: A Single-center Experience and Review of the Literature. In Vivo, 2017, 31, 51-510.	1.3	31
546	Actual 5-year survivors following resection of hilar cholangiocarcinoma Journal of Clinical Oncology, 2017, 35, 352-352.	1.6	10
547	A novel t-stage classification system for adrenocortical carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group Journal of Clinical Oncology, 2017, 35, 266-266.	1.6	Ο
548	The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis: A multi-institutional analysis Journal of Clinical Oncology, 2017, 35, 277-277.	1.6	0
549	Effect of perioperative transfusion on recurrence and survival after resection of distal cholangiocarcinoma: A 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2017, 35, 236-236.	1.6	0
550	Impact of major vascular resection on short- and long-term outcomes in patients with intrahepatic cholangiocarcinoma Journal of Clinical Oncology, 2017, 35, 275-275.	1.6	1
551	Utilizing advance care planning videos to empower perioperative cancer patients and families: Results from a randomized controlled trial Journal of Clinical Oncology, 2017, 35, 5-5.	1.6	4
552	Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. Journal of Surgical Oncology, 2016, 114, 176-180.	1.7	30
553	Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 417-426.	2.8	41
554	A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 420-426.	1.7	37
555	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 685-691.	1.7	48
556	Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7â€institution study of the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2016, 113, 750-755.	1.7	33
557	The importance of surgical margins in primary malignancies of the liver. Journal of Surgical Oncology, 2016, 113, 296-303.	1.7	50
558	Longâ€ŧerm outcomes in treatment of retroperitoneal sarcomas: A 15 year singleâ€institution evaluation of prognostic features. Journal of Surgical Oncology, 2016, 114, 56-64.	1.7	41

#	Article	IF	CITATIONS
559	Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes. Journal of Surgical Research, 2016, 206, 182-189.	1.6	38
560	Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer, 2016, 122, 2698-2707.	4.1	53
561	Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases. Journal of Surgical Oncology, 2016, 114, 361-367.	1.7	11
562	Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients undergoing resection of colorectal liver metastases: do CEA levels still have prognostic implications?. Hpb, 2016, 18, 1000-1009.	0.3	24
563	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2016, 23, 2610-2617.	1.5	128
564	Blood loss and outcomes after resection of colorectal liver metastases. Journal of Surgical Research, 2016, 202, 473-480.	1.6	37
565	A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal of Gastrointestinal Surgery, 2016, 20, 1098-1105.	1.7	33
566	Liver regeneration after major liver hepatectomy: Impact of body mass index. Surgery, 2016, 160, 81-91.	1.9	11
567	Effect of Index Hospitalization Costs on Readmission Among Patients Undergoing Major Abdominal Surgery. JAMA Surgery, 2016, 151, 718.	4.3	21
568	Impact of Perioperative Phosphorus and Glucose Levels on Liver Regeneration and Long-term Outcomes after Major Liver Resection. Journal of Gastrointestinal Surgery, 2016, 20, 1305-1316.	1.7	8
569	A Contemporary Evaluation of the Cause of Death and Longâ€Term Quality of Life After Total Pancreatectomy. World Journal of Surgery, 2016, 40, 2513-2518.	1.6	28
570	Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 1203-1211.	1.5	33
571	Packed red blood cell transfusion after surgery: are we "overtranfusing―our patients?. American Journal of Surgery, 2016, 212, 1-9.	1.8	12
572	Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: A regret-based decision curves analysis. Surgery, 2016, 160, 106-117.	1.9	23
573	Surgeon-Level Variation in Postoperative Complications. Journal of Gastrointestinal Surgery, 2016, 20, 1393-1399.	1.7	27
574	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Annals of Surgical Oncology, 2016, 23, 3016-3023.	1.5	42
575	Management of Type 9 Hepatic Arterial Anatomy at the time of Pancreaticoduodenectomy: Considerations for Preservation and Reconstruction of a Completely Replaced Common Hepatic Artery. Journal of Gastrointestinal Surgery, 2016, 20, 1400-1404.	1.7	15
576	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.5	61

#	Article	IF	CITATIONS
577	Survival Following Lung Metastasectomy in Soft Tissue Sarcomas. Thoracic and Cardiovascular Surgeon, 2016, 64, 150-158.	1.0	29
578	Reply to: epidural analgesia utilization rate for hepatic and pancreatic surgery, that low?. American Journal of Surgery, 2016, 211, 973.	1.8	1
579	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery, 2016, 211, 1106-1113.	1.8	42
580	Variation in the use of type and crossmatch blood ordering among patients undergoing hepatic and pancreatic resections. Surgery, 2016, 159, 908-918.	1.9	9
581	Validation of a Nomogram to Predict the Risk of Perioperative Blood Transfusion for Liver Resection. World Journal of Surgery, 2016, 40, 2481-2489.	1.6	18
582	National Trends in Postoperative Outcomes and Cost Comparing Minimally Invasive Versus Open Liver and Pancreatic Surgery. Journal of Gastrointestinal Surgery, 2016, 20, 1836-1843.	1.7	33
583	Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ Journal of Surgery, 2016, 86, 973-977.	0.7	23
584	Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemporary Clinical Trials, 2016, 50, 143-149.	1.8	25
585	Patterns of hepatic resections in North America: use of concurrent partial resections and ablations. Hpb, 2016, 18, 813-820.	0.3	8
586	Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 793-799.	0.3	17
587	A novel, validated risk score to predict surgical site infection after pancreaticoduodenectomy. Hpb, 2016, 18, 893-899.	0.3	41
588	Elevated NLR in gallbladder cancer and cholangiocarcinoma – making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 950-957.	0.3	50
589	The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. Hpb, 2016, 18, 700-705.	0.3	46
590	Readmission after major surgery: effect of the postdischarge environment. Journal of Surgical Research, 2016, 205, 318-326.	1.6	7
591	Impact of Delta Hemoglobin on Provider Transfusion Practices and Post-operative Morbidity Among Patients Undergoing Liver and Pancreatic Surgery. Journal of Gastrointestinal Surgery, 2016, 20, 2010-2020.	1.7	4
592	Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 872-878.	0.3	66
593	Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 2002-2009.	1.7	27
594	A crossâ€sectional study of patient and provider perception of "cure―as a goal of cancer surgery. Journal of Surgical Oncology, 2016, 114, 677-683.	1.7	13

#	Article	IF	CITATIONS
595	From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. Surgical Oncology, 2016, 25, 332-338.	1.6	21
596	Improvement of the Surgical Apgar Score by Addition of Intraoperative Blood Transfusion Among Patients Undergoing Major Gastrointestinal Surgery. Journal of Gastrointestinal Surgery, 2016, 20, 1752-1759.	1.7	13
597	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Annals of Surgical Oncology, 2016, 23, 4401-4409.	1.5	22
598	Surgical Management of Choledocholithiasis. JAMA Surgery, 2016, 151, 1130.	4.3	2
599	Variation in inpatient hospital and physician payments among patients undergoing general versus orthopedic operations. Surgery, 2016, 160, 1657-1665.	1.9	6
600	Bundled Payments for Surgical Colectomy Among Medicare Enrollees. JAMA Surgery, 2016, 151, e160202.	4.3	22
601	Actual 10â€year survivors following resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2016, 114, 971-976.	1.7	36
602	Minimally Invasive vs. Open Hepatectomy: a Comparative Analysis of the National Surgical Quality Improvement Program Database. Journal of Gastrointestinal Surgery, 2016, 20, 1608-1617.	1.7	57
603	A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 1716-1724.	1.7	31
604	Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases. Journal of Gastrointestinal Surgery, 2016, 20, 1821-1829.	1.7	61
605	Cancer surgeons' attitudes and practices about discussing the chance of operative "cure― Surgery, 2016, 160, 1619-1627.	1.9	6
606	Benchmarking the Scientific and Educational Impact of the Annals of Surgical Oncology. Annals of Surgical Oncology, 2016, 23, 2723-2729.	1.5	2
607	Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Annals of Surgical Oncology, 2016, 23, 912-920.	1.5	28
608	The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. Journal of Surgical Oncology, 2016, 114, 803-809.	1.7	73
609	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 2398-2408.	1.5	63
610	Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. Journal of Gastrointestinal Surgery, 2016, 20, 1444-1452.	1.7	16
611	Sarcopenia predicts costs among patients undergoing major abdominal operations. Surgery, 2016, 160, 1162-1171.	1.9	60
612	Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. Hpb, 2016, 18, 510-517.	0.3	33

#	Article	IF	CITATIONS
613	Variation in crystalloid administration: an analysis of 6248 patients undergoing major elective surgery. Journal of Surgical Research, 2016, 203, 368-377.	1.6	9
614	Understanding recurrent readmission after major surgery among patients with employer-provided health insurance. American Journal of Surgery, 2016, 212, 305-314.e2.	1.8	4
615	Complication timing impacts 30-d mortality after hepatectomy. Journal of Surgical Research, 2016, 203, 495-506.	1.6	17
616	Hospital readmission after multiple major operative procedures among patients withÂemployer provided healthÂinsurance. Surgery, 2016, 160, 178-190.	1.9	6
617	Hospital markup and operation outcomes in the United States. Surgery, 2016, 160, 169-177.	1.9	28
618	Effect of surgeon and anesthesiologist volume on surgical outcomes. Journal of Surgical Research, 2016, 200, 427-434.	1.6	18
619	Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surgical Oncology, 2016, 25, 190-199.	1.6	12
620	Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 1572-1580.	1.7	38
621	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	1.5	44
622	Associations Between Patient Perceptions of Communication, Cure, and Other Patient-Related Factors Regarding Patient-Reported Quality of Care Following Surgical Resection of Lung and Colorectal Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 812-826.	1.7	23
623	Cholangiocarcinoma risk factors and the potential role of aspirin. Hepatology, 2016, 64, 708-710.	7.3	10
624	Assessment of nonâ€surgical versus surgical therapy for localized hepatocellular carcinoma. Journal of Surgical Oncology, 2016, 113, 175-180.	1.7	14
625	Modified Appleby Procedure for Pancreatic Adenocarcinoma: Does Improved Neoadjuvant Therapy Warrant Such an Aggressive Approach?. Annals of Surgical Oncology, 2016, 23, 3757-3764.	1.5	56
626	Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. Annals of Surgical Oncology, 2016, 23, 3736-3743.	1.5	50
627	Inclusion of Sarcopenia Outperforms the Modified Frailty Index in Predicting 1-Year Mortality among 1,326 Patients Undergoing Gastrointestinal Surgery for a Malignant Indication. Journal of the American College of Surgeons, 2016, 222, 397-407e2.	0.5	120
628	Assessing the Costs Associated with Volume-Based Referral for Hepatic Surgery. Journal of Gastrointestinal Surgery, 2016, 20, 945-952.	1.7	17
629	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons, 2016, 222, 480-490.	0.5	71
630	Financial Impact of Postoperative Complication Following Hepato-Pancreatico-Biliary Surgery for Cancer. Annals of Surgical Oncology, 2016, 23, 1064-1070.	1.5	29

#	Article	IF	CITATIONS
631	The relative effect of hospital and surgeon volume on failure to rescue among patients undergoing liver resection for cancer. Surgery, 2016, 159, 1004-1012.	1.9	83
632	Factors Associated With Interhospital Variability in Inpatient Costs of Liver and Pancreatic Resections. JAMA Surgery, 2016, 151, 155.	4.3	28
633	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Longâ€Term Survival. World Journal of Surgery, 2016, 40, 706-714.	1.6	15
634	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 571-579.	0.8	172
635	Multidisciplinary management and the future of treatment in cholangiocarcinoma. Expert Opinion on Orphan Drugs, 2016, 4, 255-267.	0.8	2
636	Hepatocellular carcinoma: From diagnosis to treatment. Surgical Oncology, 2016, 25, 74-85.	1.6	369
637	Potential Barriers to the Diffusion of Surgical Innovation. JAMA Surgery, 2016, 151, 403.	4.3	8
638	Liver-Directed Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 67-80.	0.5	0
639	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. OncoImmunology, 2016, 5, e1083671.	4.6	56
640	Implementation Costs of an Enhanced Recovery After Surgery Program in the United States: A Financial Model and Sensitivity Analysis Based on Experiences at a Quaternary Academic Medical Center. Journal of the American College of Surgeons, 2016, 222, 219-225.	0.5	118
641	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surgery, 2016, 151, 365.	4.3	102
642	Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 1225-1233.	1.5	23
643	Crystalloid administration among patients undergoing liver surgery: Defining patient- and provider-level variation. Surgery, 2016, 159, 389-398.	1.9	12
644	Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer. Annals of Surgical Oncology, 2016, 23, 375-381.	1.5	46
645	To Roux or not to Roux: a comparison between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for gastric cancer. Gastric Cancer, 2016, 19, 994-1001.	5.3	28
646	A Systematic Review of the Factors that Patients Use to Choose their Surgeon. World Journal of Surgery, 2016, 40, 45-55.	1.6	76
647	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology, 2016, 23, 134-141.	1.5	76
648	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133.	1.5	42

#	Article	IF	CITATIONS
649	Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology, 2016, 278, 275-284.	7.3	85
650	Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Annals of Surgical Oncology, 2016, 23, 235-243.	1.5	195
651	Optimal Transfusion Trigger in Surgical Patients With Coronary Artery Disease. JAMA Surgery, 2016, 151, 146.	4.3	1
652	Gallbladder cancer presenting with jaundice: Uniformly fatal or still potentially curable?. Journal of Clinical Oncology, 2016, 34, 336-336.	1.6	1
653	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	8.4	113
654	Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. Anticancer Research, 2016, 36, 4805-4812.	1.1	22
655	Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. Hepatic Oncology, 2016, 3, 223-239.	4.2	15
656	Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surgery and Nutrition, 2016, 5, 43-52.	1.5	45
657	Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. World Journal of Gastrointestinal Surgery, 2016, 8, 27.	1.5	157
658	Impact of chemotherapy and external beam radiation therapy on outcomes among patients with resected gallbladder cancer: A multi-institutional analysis Journal of Clinical Oncology, 2016, 34, 387-387.	1.6	0
659	Conditional survival probability of long-term survival after resection of peri-hilar cholangiocarcinoma Journal of Clinical Oncology, 2016, 34, 212-212.	1.6	0
660	Impact of stereotactic body radiation therapy on patient-reported quality of life in patients with unresectable or recurrent pancreatic cancer Journal of Clinical Oncology, 2016, 34, 413-413.	1.6	0
661	The effect of postoperative morbidity on long-term survival after curative resection for extra-hepatic biliary tumors: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2016, 34, 435-435.	1.6	0
662	Rates and patterns of recurrence following complete resection of Hilar cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Consortium Journal of Clinical Oncology, 2016, 34, 324-324.	1.6	0
663	Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2016, 34, 388-388.	1.6	0
664	Effect of preoperative bilirubin on outcomes of completely resected hilar cholangiocarcinoma: A multi-institutional analysis Journal of Clinical Oncology, 2016, 34, 326-326.	1.6	0
665	Palliative treatment in extrahepatic biliary malignancies: A multi-institutional cohort Journal of Clinical Oncology, 2016, 34, 456-456.	1.6	0
666	A reappraisal of staging laparoscopy in three subtypes of cholangiocarcinoma: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2016, 34, 226-226.	1.6	0

#	Article	IF	CITATIONS
667	A multi-institutional analysis of duodenal neuroendocrine tumors: Tumor biology rather than extent of resection to dictate prognosis Journal of Clinical Oncology, 2016, 34, 255-255.	1.6	1
668	A prospective study evaluating stereotactic body radiation therapy in unresectable, recurrent, or residual pancreatic adenocarcinoma Journal of Clinical Oncology, 2016, 34, 454-454.	1.6	0
669	The optimal time-interval to re-resection for incidentally discovered gallbladder cancer: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2016, 34, 201-201.	1.6	Ο
670	A novel pathology-based preoperative risk score to predict distant and locoregional residual disease and survival for incidentally discovered gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium Journal of Clinical Oncology, 2016, 34, 202-202.	1.6	0
671	Optimal prognostic lymph node staging system for gallbladder adenocarcinoma: A multi-institutional study Journal of Clinical Oncology, 2016, 34, 364-364.	1.6	Ο
672	Can video recording revolutionise medical quality?. BMJ, The, 2015, 351, h5169.	6.0	21
673	Understanding Variation in 30-Day Surgical Readmission in the Era of Accountable Care. JAMA Surgery, 2015, 150, 1042.	4.3	74
674	Understanding drivers of hospital charge variation for episodes of care among patients undergoing hepatopancreatobiliary surgery. Hpb, 2015, 17, 955-963.	0.3	12
675	What to expect when you're expecting a hepatopancreatobiliary surgeon: self-reported experiences of HPB surgeons from different training pathways. Hpb, 2015, 17, 785-790.	0.3	19
676	National trends with a laparoscopic liver resection: results from a population based analysis. Hpb, 2015, 17, 919-926.	0.3	67
677	Can hepatic resection provide a longâ€ŧerm cure for patients with intrahepatic cholangiocarcinoma?. Cancer, 2015, 121, 3998-4006.	4.1	131
678	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer, 2015, 121, 3564-3573.	4.1	50
679	Reply to patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer, 2015, 121, 4444-4445.	4.1	Ο
680	Neutrophilâ€lymphocyte and plateletâ€lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36
681	Training in Hepatopancreatobiliary Surgery. Annals of Surgery, 2015, 262, 1065-1070.	4.2	18
682	Impact of complications on longâ€ŧerm survival after resection of intrahepatic cholangiocarcinoma. Cancer, 2015, 121, 2730-2739.	4.1	61
683	The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multiâ€institutional study of the US Gastric Cancer Collaborative. Journal of Surgical Oncology, 2015, 112, 203-207.	1.7	35
684	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A sevenâ€institution analysis of 837 patients from the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2015, 112, 195-202.	1.7	26

#	Article	IF	CITATIONS
685	Early Versus Late Readmission After Surgery Among Patients With Employer-provided Health Insurance. Annals of Surgery, 2015, 262, 502-511.	4.2	53
686	Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterology Research and Practice, 2015, 2015, 1-14.	1.5	35
687	Doing More: Trends in Breast Cancer Surgery, 2005 to 2011. American Surgeon, 2015, 81, 74-80.	0.8	33
688	Readmission After Liver Resection for Intrahepatic Cholangiocarcinoma: a Multi-Institutional Analysis. Journal of Gastrointestinal Surgery, 2015, 19, 1334-1341.	1.7	12
689	Perioperative Management of Hilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 1889-1899.	1.7	68
690	Tracking Early Readmission After Pancreatectomy to Index and Nonindex Institutions. JAMA Surgery, 2015, 150, 152.	4.3	39
691	The impact of resident involvement onÂsurgical outcomes among patients undergoing hepatic and pancreatic resections. Surgery, 2015, 158, 323-330.	1.9	40
692	Correlation of Clinical Stage and Performance Status With Quality of Life in Patients Seen in a Pancreas Multidisciplinary Clinic. Journal of Oncology Practice, 2015, 11, e216-e221.	2.5	36
693	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 2154-2161.	1.7	2
694	Intrahepatic Cholangiocarcinoma: expert consensus statement. Hpb, 2015, 17, 669-680.	0.3	372
695	Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. American Journal of Surgery, 2015, 210, 636-642.e1.	1.8	9
696	Sarcopenia Adversely Impacts Postoperative Complications Following Resection or Transplantation in Patients with Primary Liver Tumors. Journal of Gastrointestinal Surgery, 2015, 19, 272-281.	1.7	185
697	The evolving field of intrahepatic cholangiocarcinoma. Hepatic Oncology, 2015, 2, 5-8.	4.2	0
698	Defining Post Hepatectomy Liver Insufficiency: Where do We stand?. Journal of Gastrointestinal Surgery, 2015, 19, 2079-2092.	1.7	92
699	Effect of Relative Decrease in Blood Hemoglobin Concentrations on Postoperative Morbidity in Patients Who Undergo Major Gastrointestinal Surgery. JAMA Surgery, 2015, 150, 949.	4.3	48
700	Metabolic syndrome-associated hepatocellular carcinoma: Questions still unanswered. Journal of Hepatology, 2015, 63, 8-9.	3.7	7
701	Patterns of care among patients undergoing hepatic resection: a query of the National Surgical Quality Improvement Program-targeted hepatectomy database. Journal of Surgical Research, 2015, 196, 221-228.	1.6	46
702	Early versus late hospital readmission after pancreaticoduodenectomy. Journal of Surgical Research, 2015, 196, 74-81.	1.6	16

#	Article	IF	CITATIONS
703	Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology, 2015, 277, 594-603.	7.3	31
704	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: AÂMarkov decision model. Surgery, 2015, 158, 339-348.	1.9	23
705	See one, do one, and teach none: resident experience as a teaching assistant. Journal of Surgical Research, 2015, 195, 44-51.	1.6	38
706	Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A 7-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 767-777.	0.5	70
707	Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia. Journal of Gastrointestinal Surgery, 2015, 19, 1593-1602.	1.7	196
708	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Costâ€Utility Analysis. World Journal of Surgery, 2015, 39, 2500-2509.	1.6	17
709	Quality of life after treatment of neuroendocrine liver metastasis. Journal of Surgical Research, 2015, 198, 155-164.	1.6	34
710	Value of Peritoneal Drain Placement After Total Gastrectomy for Gastric Adenocarcinoma: A Multi-institutional Analysis from the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 888-897.	1.5	16
711	Potential Economic Impact of Using a Restrictive Transfusion Trigger Among Patients Undergoing Major Abdominal Surgery. JAMA Surgery, 2015, 150, 625.	4.3	35
712	Association Between Specific Mutations in <i>KRAS</i> Codon 12 and Colorectal Liver Metastasis. JAMA Surgery, 2015, 150, 722.	4.3	108
713	Factors That Determine Cancer Treatment Choice Among Minority Groups. Journal of Oncology Practice, 2015, 11, 259-261.	2.5	20
714	Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 4158-4165.	1.5	86
715	Presentation and Clinical Outcomes of Choledochal Cysts in Children and Adults. JAMA Surgery, 2015, 150, 577.	4.3	98
716	Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. Journal of Surgical Research, 2015, 195, 74-82.	1.6	66
717	Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. Journal of Gastrointestinal Surgery, 2015, 19, 1581-1592.	1.7	129
718	Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2015, 150, 538.	4.3	91
719	Surgical Management of Intrahepatic Cholangiocarcinoma: Defining an Optimal Prognostic Lymph Node Stratification Schema. Annals of Surgical Oncology, 2015, 22, 2772-2778.	1.5	47
720	The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 4020-4028.	1.5	126

#	Article	IF	CITATIONS
721	The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma. World Journal of Surgery, 2015, 39, 1474-1484.	1.6	37
722	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 3716-3723.	1.5	83
723	Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. Annals of Surgical Oncology, 2015, 22, 1100-1106.	1.5	32
724	A nationwide analysis of the use and outcomes of perioperative epidural analgesia in patients undergoing hepatic and pancreatic surgery. American Journal of Surgery, 2015, 210, 483-491.	1.8	43
725	Red Cell Transfusion Triggers and Postoperative Outcomes After Major Surgery. Journal of Gastrointestinal Surgery, 2015, 19, 2062-2073.	1.7	24
726	National trends in the use of surgery for benign hepatic tumors in the United States. Surgery, 2015, 157, 1055-1064.	1.9	27
727	Intrahepatic Cholangiocarcinoma: Prognosis of Patients Who Did Not Undergo Lymphadenectomy. Journal of the American College of Surgeons, 2015, 221, 1031-1040e4.	0.5	61
728	Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2015, 22, 4382-4391.	1.5	95
729	The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 832-839.	1.5	28
730	Long-term therapy with sorafenib is associated with pancreatic atrophy. Journal of Surgical Research, 2015, 199, 314-321.	1.6	10
731	Sex- and age-based variation inÂtransfusion practices among patients undergoing major surgery. Surgery, 2015, 158, 1372-1381.	1.9	14
732	Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2015, 19, 2273-2282.	1.7	21
733	The Role of Radiation Therapy in Pancreatic Ductal Adenocarcinoma in the Neoadjuvant and Adjuvant Settings. Seminars in Oncology, 2015, 42, 144-162.	2.2	21
734	Advances in understanding of colorectal liver metastasis and implications for the clinic. Expert Review of Gastroenterology and Hepatology, 2015, 9, 245-259.	3.0	22
735	Enhanced Recovery After Surgery Protocols for Open Hepatectomy—Physiology, Immunomodulation, and Implementation. Journal of Gastrointestinal Surgery, 2015, 19, 387-399.	1.7	62
736	Epidemiology of Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2015, 24, 1-17.	1.5	256
737	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 557-564.	1.5	61
738	Use of Endoscopic Ultrasound in the Preoperative Staging of Gastric Cancer: A Multi-Institutional Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 220, 48-56.	0.5	58

#	Article	IF	CITATIONS
739	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. , 2015, 121, 3564.		1
740	The prognostic value of signet ring cell histology in resected gastric cancer Journal of Clinical Oncology, 2015, 33, 128-128.	1.6	1
741	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. Journal of Gastrointestinal Oncology, 2015, 6, 115-25.	1.4	22
742	The optimal length of the proximal resection margin in patients with proximal gastric adenocarcinoma: A multi-institutional study of the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2015, 33, 108-108.	1.6	0
743	Surgical outcomes of patients with pancreatic cancer treated with stereotactic body radiation therapy Journal of Clinical Oncology, 2015, 33, 341-341.	1.6	1
744	Value of peritoneal drain placement after total gastrectomy for gastric adenocarcinoma: A multi-institutional analysis from the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2015, 33, 131-131.	1.6	0
745	Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative intent surgical resection Journal of Clinical Oncology, 2015, 33, 349-349.	1.6	0
746	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy Journal of Clinical Oncology, 2015, 33, 353-353.	1.6	0
747	The prognostic value of preoperative helicobacter pylori infection in resected gastric cancer Journal of Clinical Oncology, 2015, 33, 137-137.	1.6	0
748	Optimal extent of lymphadenectomy in gastric adenocarcinoma: A seven-institution study of the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2015, 33, 115-115.	1.6	0
749	Is linitis plastica a contraindication for surgical resection? A 7-institution study of the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2015, 33, 118-118.	1.6	Ο
750	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A seven-institution analysis of 837 patients from the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2015, 33, 120-120.	1.6	0
751	Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary cancers Journal of Clinical Oncology, 2015, 33, 378-378.	1.6	Ο
752	Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases Journal of Clinical Oncology, 2015, 33, 282-282.	1.6	0
753	Patient- versus physician-reported outcomes in patients enrolled in a prospective study involving stereotactic body radiation therapy in unresectable or recurrent pancreatic cancer Journal of Clinical Oncology, 2015, 33, 84-84.	1.6	8
754	Engaging patients and stakeholders in the process of designing a clinical trial and patient education platform Journal of Clinical Oncology, 2015, 33, 63-63.	1.6	3
755	Stereotactic body radiation therapy and patient-reported quality of life prospectively evaluated in patients with unresectable or recurrent pancreatic cancer Journal of Clinical Oncology, 2015, 33, 92-92.	1.6	1
756	Endometrial stromal sarcoma presenting as large bleeding left upper quadrant mass. Hepatobiliary Surgery and Nutrition, 2015, 4, 363-6.	1.5	0

#	Article	IF	CITATIONS
757	Management of borderline and locally advanced pancreatic cancer: Where do we stand?. World Journal of Gastroenterology, 2014, 20, 2255.	3.3	76
758	Liver-Directed Therapies: Surgical Approaches, Alone and in Combination with Other Interventions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 101-110.	3.8	9
759	A minimally invasive technique utilizing percutaneous and endoscopic rendezvous for successful treatment of a proximal bile leak following partial hepatectomy. Endoscopy, 2014, 46, E212-E213.	1.8	12
760	Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis. Journal of Surgical Oncology, 2014, 110, 163-170.	1.7	94
761	Readmission incidence and associated factors after a hepatic resection at a major hepato-pancreatico-biliary academic centre. Hpb, 2014, 16, 972-978.	0.3	40
762	Variation in Readmission by Hospital After Colorectal Cancer Surgery. JAMA Surgery, 2014, 149, 1272.	4.3	37
763	A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2014, 259, 204-212.	4.2	138
764	Hospital Volume and Patient Outcomes in Hepato-Pancreatico-Biliary Surgery: Is Assessing Differences in Mortality Enough?. Journal of Gastrointestinal Surgery, 2014, 18, 2105-2115.	1.7	65
765	A Nomogram to Predict Long-term Survival After Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2014, 149, 432.	4.3	285
766	Avoiding Immortal Time Bias in the American College of Surgeons National Surgical Quality Improvement Program Readmission Measure. JAMA Surgery, 2014, 149, 875.	4.3	17
767	Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2014, 149, 565.	4.3	585
768	Indeterminate Left-Sided Retroperitoneal Mass. JAMA Surgery, 2014, 149, 991.	4.3	0
769	Quality improvement in gastrointestinal surgical oncology with American College of Surgeons National Surgical Quality Improvement Program. Surgery, 2014, 155, 593-601.	1.9	45
770	Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2014, 23, xv-xvi.	1.5	1
771	Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes inÂPatients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 539-546.	0.8	70
772	Identifying Variations in Blood Use Based on Hemoglobin Transfusion Trigger and Target among Hepatopancreaticobiliary Surgeons. Journal of the American College of Surgeons, 2014, 219, 217-228.	0.5	59
773	Assessing the experience in complex hepatopancreatobiliary surgery among graduating chief residents: Is the operative experience enough?. Surgery, 2014, 156, 385-393.	1.9	39
774	Interhospital Transfer and Adverse Outcomes after General Surgery: Implications for Pay for Performance. Journal of the American College of Surgeons, 2014, 218, 393-400.	0.5	50

#	Article	IF	CITATIONS
775	Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. European Journal of Radiology, 2014, 83, 487-496.	2.6	63
776	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology, 2014, 60, 1268-1289.	3.7	1,151
777	Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma: A National Perspective. Journal of the American College of Surgeons, 2014, 218, 196-205.	0.5	75
778	Imaging of the Patient with a Biliary Tract or Primary Liver Tumor. Surgical Oncology Clinics of North America, 2014, 23, 189-206.	1.5	9
779	Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2014, 23, 289-311.	1.5	58
780	Recurrence Patterns and Prognostic Factors in Patients with Hepatocellular Carcinoma in Noncirrhotic Liver: A Multi-Institutional Analysis. Annals of Surgical Oncology, 2014, 21, 147-154.	1.5	68
781	Cystic Neoplasms of the Liver: Biliary Cystadenoma and Cystadenocarcinoma. Journal of the American College of Surgeons, 2014, 218, 119-128.	0.5	135
782	Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. Journal of Gastrointestinal Surgery, 2014, 18, 2136-2148.	1.7	90
783	Choledochal Cysts: Presentation, Clinical Differentiation, and Management. Journal of the American College of Surgeons, 2014, 219, 1167-1180.	0.5	193
784	Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. Hpb, 2014, 16, 1117-1126.	0.3	43
785	Cholecystectomy and Wound Complications: Smoking Worsens Risk. Journal of Surgical Research, 2014, 192, 41-49.	1.6	5
786	Long-Term Health-Related Quality of Life after Iatrogenic Bile Duct Injury Repair. Journal of the American College of Surgeons, 2014, 219, 923-932e10.	0.5	46
787	Race-based differences in length of stay among patients undergoing pancreatoduodenectomy. Surgery, 2014, 156, 528-537.	1.9	14
788	Worse outcomes among uninsured general surgery patients: Does the need for an emergency operation explain these disparities?. Surgery, 2014, 156, 345-351.	1.9	74
789	Readmission After Surgery. Advances in Surgery, 2014, 48, 185-199.	1.3	84
790	Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbeck's Archives of Surgery, 2014, 399, 679-692.	1.9	29
791	The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 2873-2881.	1.5	184
792	Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. Annals of Surgical Oncology, 2014, 21, 3827-3834.	1.5	123

#	Article	IF	CITATIONS
793	Tumor Size Predicts Vascular Invasion and Histologic Grade Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2014, 18, 1284-1291.	1.7	65
794	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. Journal of the American College of Surgeons, 2014, 219, 664-675.	0.5	139
795	A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample. Surgery, 2014, 156, 538-547.	1.9	60
796	Inpatient survival after gastrectomy for gastric cancer in the 21st century. Journal of Surgical Research, 2014, 190, 72-78.	1.6	5
797	Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity scoreâ~'matched Surveillance, Epidemiology, and End Results analysis. Surgery, 2014, 155, 85-93.	1.9	40
798	Alternative Lengthening of Telomeres Predicts Site of Origin in Neuroendocrine Tumor Liver Metastases. Journal of the American College of Surgeons, 2014, 218, 628-635.	0.5	34
799	The timing of complications impacts risk of readmission after hepatopancreatobiliary surgery. Surgery, 2014, 155, 945-953.	1.9	43
800	Choosing a Cancer Surgeon: Analyzing Factors in Patient Decision Making Using a Best–Worst Scaling Methodology. Annals of Surgical Oncology, 2014, 21, 3732-3738.	1.5	46
801	Stereotactic body radiation therapy for pancreatic cancer: Single institutional experience Journal of Clinical Oncology, 2014, 32, 328-328.	1.6	4
802	Factors associated with recurrence in lymph node-negative gastric adenocarcinoma: Results from the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2014, 32, 80-80.	1.6	1
803	Organizing a multidisciplinary clinic. Chinese Clinical Oncology, 2014, 3, 43.	1.2	15
804	Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surgery and Nutrition, 2014, 3, 18-34.	1.5	82
805	Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognostic determinants and identifying therapeutic targets Journal of Clinical Oncology, 2014, 32, 210-210.	1.6	2
806	The effect of perioperative transfusion on recurrence and survival following gastric cancer resection: A seven-institution analysis of 765 patients from the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2014, 32, 100-100.	1.6	0
807	Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: A multi-institutional analysis Journal of Clinical Oncology, 2014, 32, 84-84.	1.6	0
808	Pre-SBRT metabolic tumor volume and total lesion glycolysis to predict survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy Journal of Clinical Oncology, 2014, 32, 189-189.	1.6	1
809	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas Journal of Clinical Oncology, 2014, 32, 269-269.	1.6	15
810	Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative Journal of Clinical Oncology, 2014, 32, 103-103.	1.6	0

#	Article	IF	CITATIONS
811	Open versus minimally invasive management of gastric GIST: An international multi-institutional analysis of short- and long-term outcomes Journal of Clinical Oncology, 2014, 32, 85-85.	1.6	0
812	Effects of gemcitabine and stereotactic body radiotherapy on quality of life in locally advanced pancreatic cancer Journal of Clinical Oncology, 2014, 32, 278-278.	1.6	0
813	The effect of postoperative morbidity on survival after resection for gastric adenocarcinoma: Results from the U.S. Gastric Cancer Collaborative Journal of Clinical Oncology, 2014, 32, 5-5.	1.6	1
814	Prognostic factors after pancreaticoduodenectomy for duodenal adenocarcinoma: Results from a dual center analysis Journal of Clinical Oncology, 2014, 32, e15181-e15181.	1.6	0
815	Association of recurrence patterns following resection of pancreatic adenocarcinoma with overall survival Journal of Clinical Oncology, 2014, 32, 4127-4127.	1.6	2
816	Choosing a cancer surgeon: Analyzing factors in patient decision making using a best-worst scaling methodology Journal of Clinical Oncology, 2014, 32, 6551-6551.	1.6	0
817	Difference in outcomes among patients undergoing open versus laparoscopy-assisted approach for gastric cancer: A multi-institutional analysis Journal of Clinical Oncology, 2014, 32, 4082-4082.	1.6	0
818	Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: A multi-institutional analysis Journal of Clinical Oncology, 2014, 32, 4011-4011.	1.6	0
819	Patterns of Consultation and Treatment of Patients with Hepatocellular Carcinoma Presenting to a Large Academic Medical Center in the US. Journal of Gastrointestinal Surgery, 2013, 17, 1600-1608.	1.7	16
820	Referral Patterns and Treatment Choices for Patients with Hepatocellular Carcinoma: A United States Population-Based Study. Journal of the American College of Surgeons, 2013, 217, 896-906.	0.5	47
821	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships. Journal of Radiation Oncology, 2013, 2, 413-425.	0.7	74
822	Impact of Hospital Teaching Status on Length of Stay and Mortality Among Patients Undergoing Complex Hepatopancreaticobiliary Surgery in the USA. Journal of Gastrointestinal Surgery, 2013, 17, 2114-2122.	1.7	55
823	Emerging Approaches in the Management of Patients with Neuroendocrine Liver Metastasis: Role of Liver-Directed and Systemic Therapies. Journal of the American College of Surgeons, 2013, 216, 123-134.	0.5	66
824	Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery, 2013, 153, 811-818.	1.9	239
825	Provider versus patient factors impacting hospital length of stay after pancreaticoduodenectomy. Surgery, 2013, 154, 152-161.	1.9	51
826	Surgical Management of Patients with Synchronous Colorectal Liver Metastasis: A Multicenter International Analysis. Journal of the American College of Surgeons, 2013, 216, 707-716.	0.5	159
827	Trends and Patterns of Utilization in Post-treatment Surveillance Imaging Among Patients Treated for Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 1774-1783.	1.7	23
828	Influence of Patient, Physician, and Hospital Factors on 30-Day Readmission Following Pancreatoduodenectomy in the United States. JAMA Surgery, 2013, 148, 1095.	4.3	137

#	Article	IF	CITATIONS
829	Surgical Therapy for Early Hepatocellular Carcinoma in the Modern Era. Annals of Surgery, 2013, 258, 1022-1027.	4.2	59
830	Local Therapies for Hepatic Metastases. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 153-160.	4.9	24
831	Surgery for colorectal liver metastases: The evolution of determining prognosis. World Journal of Gastrointestinal Oncology, 2013, 5, 207.	2.0	64
832	Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer Journal of Clinical Oncology, 2013, 31, 269-269.	1.6	1
833	Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma Journal of Clinical Oncology, 2013, 31, 285-285.	1.6	0
834	Duodenal and ampullary carcinoid tumors: Using size to predict necessity for lymphadenectomy Journal of Clinical Oncology, 2013, 31, 316-316.	1.6	1
835	Understanding variations in referral patterns and treatment choices for patients with hepatocellular carcinoma Journal of Clinical Oncology, 2013, 31, 293-293.	1.6	0
836	Hemoglobin-A1c level to predict for clinical outcomes in patients with pancreatic cancer Journal of Clinical Oncology, 2013, 31, 4039-4039.	1.6	1
837	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas Journal of Clinical Oncology, 2013, 31, e15028-e15028.	1.6	1
838	Prospective phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: Efficacy analysis Journal of Clinical Oncology, 2013, 31, 4124-4124.	1.6	0
839	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. Journal of Clinical Oncology, 2013, 31, 4057-4057.	1.6	1
840	Priorities for Hepatocellular Carcinoma (HCC) Control: A Comparison of Policy Needs in Five European Countries. Journal of Comparative Policy Analysis: Research and Practice, 2012, 14, 352-368.	2.9	4
841	Patient Readmission and Mortality after Surgery for Hepato-Pancreato-Biliary Malignancies. Journal of the American College of Surgeons, 2012, 215, 607-615.	0.5	106
842	Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and Outcomes. Annals of Surgical Oncology, 2012, 19, 2897-2907.	1.5	86
843	Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery, 2012, 152, 218-226.	1.9	103
844	Risk of Morbidity and Mortality Following Hepato-Pancreato-Biliary Surgery. Journal of Gastrointestinal Surgery, 2012, 16, 1727-1735.	1.7	227
845	National trends in surgical procedures for hepatocellular carcinoma: 1998â€2008. Cancer, 2012, 118, 1838-1844.	4.1	49
846	Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer, 2012, 118, 2674-2681.	4.1	132

#	Article	IF	CITATIONS
847	The impact of portal vein resection on outcomes for hilar cholangiocarcinoma. Cancer, 2012, 118, 4737-4747.	4.1	180
848	Multidisciplinary Management of Recurrent Hepatocellular Carcinoma Following Liver Transplantation. Journal of Gastrointestinal Surgery, 2012, 16, 874-881.	1.7	31
849	Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 2012, 16, 1478-1486.	1.7	449
850	Patient Readmission and Mortality after Colorectal Surgery for Colon Cancer: Impact of Length of Stay Relative to Other Clinical Factors. Journal of the American College of Surgeons, 2012, 214, 390-398.	0.5	235
851	Variations in surgical outcomes associated with hospital compliance with safety practices. Surgery, 2012, 151, 651-659.	1.9	51
852	Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases Journal of Clinical Oncology, 2012, 30, 3616-3616.	1.6	3
853	Multiparametric quantitative functional MRI for assessing early changes in volumetric functional tumor burden in hepatocellular carcinoma treated by intra-arterial therapies Journal of Clinical Oncology, 2012, 30, 4114-4114.	1.6	0
854	Treating patients with colorectal liver metastasis: A national decision-making analysis to understand choice of therapy Journal of Clinical Oncology, 2012, 30, 3596-3596.	1.6	4
855	Patient retention and costs associated with a pancreatic multidisciplinary clinic Journal of Clinical Oncology, 2012, 30, 96-96.	1.6	0
856	Preliminary decision-tree analysis of costs to payors associated with a pancreatic multidisciplinary clinic Journal of Clinical Oncology, 2012, 30, 118-118.	1.6	0
857	Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. Journal of Clinical Oncology, 2011, 29, 3140-3145.	1.6	615
858	Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Annals of Surgical Oncology, 2011, 18, 3657-3665.	1.5	151
859	Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma. Journal of Clinical Oncology, 2011, 29, 3960-3967.	1.6	279
860	Hereditary Pancreatic and Hepatobiliary Cancers. International Journal of Surgical Oncology, 2011, 2011, 1-10.	0.6	10
861	Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. Hpb, 2011, 13, 439-446.	0.3	345
862	Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. Hpb, 2011, 13, 473-482.	0.3	140
863	Surgical Management and Emerging Therapies to Prolong Survival in Metastatic Neuroendocrine Cancer. Annals of Surgical Oncology, 2011, 18, 220-221.	1.5	11
864	Liver Resection for Colorectal Metastases in Presence of Extrahepatic Disease: Results from an International Multi-institutional Analysis. Annals of Surgical Oncology, 2011, 18, 1380-1388.	1.5	138

#	Article	IF	CITATIONS
865	Variation in Lymph Node Assessment After Colon Cancer Resection: Patient, Surgeon, Pathologist, or Hospital?. Journal of Gastrointestinal Surgery, 2011, 15, 471-479.	1.7	74
866	The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?. Journal of Gastrointestinal Surgery, 2011, 15, 410-415.	1.7	11
867	The Effect of Steatosis on Echogenicity of Colorectal Liver Metastases on Intraoperative Ultrasonography. Archives of Surgery, 2010, 145, 661.	2.2	27
868	Emerging Therapeutic Approaches to Hepatocellular Carcinoma. Annals of Surgical Oncology, 2010, 17, 1217-1218.	1.5	1
869	Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis. Annals of Surgical Oncology, 2010, 17, 3129-3136.	1.5	400
870	Impact of Obesity on Perioperative Outcomes and Survival Following Pancreaticoduodenectomy for Pancreatic Cancer: A Large Single-Institution Study. Journal of Gastrointestinal Surgery, 2010, 14, 1143-1150.	1.7	87
871	Conditional Survival after Surgical Resection of Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 949 Patients. Journal of the American College of Surgeons, 2010, 210, 755-764.	0.5	119
872	Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. Hpb, 2010, 12, 289-299.	0.3	163
873	Intrahepatic Cholangiocarcinoma. Surgical Clinics of North America, 2010, 90, 817-837.	1.5	104
874	The Volume-Outcomes Effect in Hepato-Pancreato-Biliary Surgery: Hospital Versus Surgeon Contributions and Specificity of the Relationship. Journal of the American College of Surgeons, 2009, 208, 528-538.	0.5	186
875	Debate: Resection for Early Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2009, 13, 1026-1028.	1.7	7
876	Repeat Curative Intent Liver Surgery is Safe and Effective for Recurrent Colorectal Liver Metastasis: Results from an International Multi-institutional Analysis. Journal of Gastrointestinal Surgery, 2009, 13, 2141-2151.	1.7	165
877	A Proposed Staging System for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2009, 16, 14-22.	1.5	294
878	Timing of Multimodality Therapy for Resectable Synchronous Colorectal Liver Metastases: A Retrospective Multi-Institutional Analysis. Annals of Surgical Oncology, 2009, 16, 1809-1819.	1.5	92
879	Trends in Nontherapeutic Laparotomy Rates in Patients Undergoing Surgical Therapy for Hepatic Colorectal Metastases. Annals of Surgical Oncology, 2009, 16, 371-378.	1.5	35
880	Liver Cell Adenoma: A Multicenter Analysis of Risk Factors for Rupture and Malignancy. Annals of Surgical Oncology, 2009, 16, 640-648.	1.5	203
881	Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis. Annals of Surgery, 2009, 250, 440-448.	4.2	664
882	Operative Mortality After Hepatic Resection: Are Literature-Based Rates Broadly Applicable?. Journal of Gastrointestinal Surgery, 2008, 12, 842-851.	1.7	137

#	Article	IF	CITATIONS
883	Two-stage hepatectomy for colorectal cancer hepatic metastases. Current Colorectal Cancer Reports, 2008, 4, 93-99.	0.5	4
884	Limitations of Claims and Registry Data in Surgical Oncology Research. Annals of Surgical Oncology, 2008, 15, 415-423.	1.5	209
885	Surgical Margins during Hepatic Surgery for Colorectal Liver Metastases: Complete Resection not Millimeters Defines Outcome. Annals of Surgical Oncology, 2008, 15, 677-679.	1.5	46
886	Evaluating the Impact of a Single-Day Multidisciplinary Clinic on the Management of Pancreatic Cancer. Annals of Surgical Oncology, 2008, 15, 2081-2088.	1.5	235
887	Malignant transformation of hepatic adenomas. Modern Pathology, 2008, 21, 491-497.	5.5	126
888	Primary Sclerosing Cholangitis: Role of Extrahepatic Biliary Resection. Journal of the American College of Surgeons, 2008, 206, 822-830.	0.5	22
889	Racial Disparity in Surgical Mortality after Major Hepatectomy. Journal of the American College of Surgeons, 2008, 207, 312-319.	0.5	53
890	Expanding Criteria for Resectability of Colorectal Liver Metastases. Oncologist, 2008, 13, 51-64.	3.7	389
891	Pregnancy Outcomes after Bariatric Surgery. Bariatric Nursing and Surgical Patient Care, 2007, 2, 113-118.	0.1	1
892	Preoperative Assessment of Hepatocellular Carcinoma Tumor Grade Using Needle Biopsy. Annals of Surgery, 2007, 245, 435-442.	4.2	187
893	The role of radiation in retroperitoneal sarcomas: a surgical perspective. Current Opinion in Oncology, 2007, 19, 359-366.	2.4	39
894	Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery, 2007, 141, 610-618.	1.9	408
895	Liver-Directed Surgery for Metastatic Squamous Cell Carcinoma to the Liver: Results of a Multi-Center Analysis. Annals of Surgical Oncology, 2007, 14, 2807-2816.	1.5	89
896	Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Current Oncology Reports, 2007, 9, 193-201.	4.0	17
897	Surgical Therapy for Colorectal Metastases to the Liver. Journal of Gastrointestinal Surgery, 2007, 11, 1057-1077.	1.7	206
898	Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome. Journal of Gastrointestinal Surgery, 2007, 11, 860-868.	1.7	237
899	Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis. Journal of Gastrointestinal Surgery, 2007, 11, 1488-1497.	1.7	214
900	Incidence of Finding Residual Disease for Incidental Gallbladder Carcinoma: Implications for Re-resection. Journal of Gastrointestinal Surgery, 2007, 11, 1478-1487.	1.7	242

#	Article	IF	CITATIONS
901	Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease. Annals of Surgical Oncology, 2006, 13, 712-720.	1.5	133
902	Long-Term Results of Two Prospective Trials of Preoperative External Beam Radiotherapy for Localized Intermediate- or High-Grade Retroperitoneal Soft Tissue Sarcoma. Annals of Surgical Oncology, 2006, 13, 508-517.	1.5	234
903	Comparison Between Hepatic Wedge Resection and Anatomic Resection for Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2006, 10, 86-94.	1.7	143
904	Debunking Dogma: Surgery for Four or More Colorectal Liver Metastases Is Justified. Journal of Gastrointestinal Surgery, 2006, 10, 240-248.	1.7	92
905	Pelvic Exenteration for Advanced Pelvic Malignancies. Annals of Surgical Oncology, 2006, 13, 612-623.	1.5	115
906	Withholding and Withdrawing Life-Sustaining Treatment: A Surgeon's Perspective. Journal of the American College of Surgeons, 2006, 202, 990-994.	0.5	8
907	Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer, 2006, 6, 68.	2.6	117
908	Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer, 2006, 106, 900-906.	4.1	122
909	Acne Vulgaris: False-Positive Finding on Integrated18F-FDG PET/CT in a Patient with Melanoma. American Journal of Roentgenology, 2006, 187, W117-W119.	2.2	7
910	Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver. Archives of Surgery, 2006, 141, 537.	2.2	156
911	Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases. Annals of Surgery, 2005, 241, 715-724.	4.2	966
912	Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy. Annals of Surgical Oncology, 2005, 12, 587-596.	1.5	192
913	Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: Results of a multicenter study. Surgery, 2005, 137, 403-410.	1.9	215
914	Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplantation, 2005, 11, 1086-1092.	2.4	555
915	Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Research and Treatment, 2005, 89, 149-157.	2.5	98
916	Accelerated Partial Breast Irradiation as an Alternative to Whole-Breast Irradiation in Breast-Conserving Therapy for Early-Stage Breast Cancer. Women's Health, 2005, 1, 59-71.	1.5	1
917	Critical Appraisal of the Clinical and Pathologic Predictors of Survival After Resection of Large Hepatocellular Carcinoma. Archives of Surgery, 2005, 140, 450.	2.2	203
918	Accelerated partial breast irradiation as an alternative to whole breast irradiation in breast-conserving therapy for early-stage breast cancer. Women's Health, 2005, 1, 59-71.	1.5	3

#	Article	IF	CITATIONS
919	The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph Nodes. Journal of Clinical Oncology, 2005, 23, 4588-4590.	1.6	114
920	Ethical Issues in Surgical Palliative Care: Am I Killing the Patient by "Letting Him Go�. Surgical Clinics of North America, 2005, 85, 273-286.	1.5	15
921	The evolving role of proteomics in the early detection of breast cancer. International Journal of Fertility and Women's Medicine, 2005, 50, 212-6.	0.4	4
922	Colorectal Carcinogenesis: MSI-H Versus MSI-L. Disease Markers, 2004, 20, 199-206.	1.3	116
923	The biologic rationale for and emerging role of accelerated partial breast irradiation for breast cancer. Journal of the American College of Surgeons, 2004, 199, 479-492.	0.5	33
924	Lymphatic Mapping in the Molecular Era. Annals of Surgical Oncology, 2004, 11, 362-374.	1.5	23
925	Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 928-942.	0.8	870
926	Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer, 2004, 100, 490-498.	4.1	34
927	Surgical treatment of hepatocellular carcinoma: Similar long-term results despite geographic variations. Liver Transplantation, 2004, 10, S74-S80.	2.4	35
928	Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. Journal of Gastrointestinal Surgery, 2004, 8, 794-805.	1.7	32
929	Advances in the Surgical Management of Liver Malignancies. Cancer Journal (Sudbury, Mass), 2004, 10, 74-87.	2.0	19
930	Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients. Annals of Surgical Oncology, 2003, 10, 1059-1069.	1.5	284
931	Central role of interleukin-6 in burn induced stimulation of hepatic amino acid transport. International Journal of Molecular Medicine, 2003, 12, 541-8.	4.0	8
932	Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer, 2002, 95, 1171-1181.	4.1	73
933	Primary Pancreatic Adenocarcinoma. , 0, , 498-542.		0